STOCK TITAN

OneMedNet flags going-concern doubt, cash at $137K

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
424B3

Rhea-AI Filing Summary

OneMedNet Corporation (ONMD) updated its prospectus with its quarter ended September 30, 2026 report, which lists a primary offering of up to 1,150,000 common shares and a secondary offering of up to 2,815,256 common shares. For the quarter, revenue was $1.023 million, up 478% from $177,000 a year earlier, while net loss was $2.660 million versus $741,000. Cost of revenue was $1.386 million, resulting in a $363,000 gross loss.

At September 30, cash and cash equivalents were $137,000 and accumulated deficit was $111.655 million. Management said cash was not adequate to fund operations through at least 12 months from issuance, raising substantial doubt about the company’s ability to continue as a going concern. Separately, a 2026 agreement permits, but does not require, stock sales of up to $25.0 million over 36 months, subject to conditions including effectiveness of a resale registration statement. In October 2026, OneMedNet received approximately $1.0 million for 174,884 shares under related-party subscriptions.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 3 points

How the balance works

Positive

  • Moderate pointQuarterly revenue rose 478% to $1.023 million.

Negative

  • Major pointGoing-concern doubt: $137,000 cash was inadequate to fund operations through at least 12 months.
  • Moderate pointQuarterly net loss widened to $2.660 million from $741,000.
  • Minor pointQuarterly gross loss increased 64% to $363,000.
Primary offering Up to 1,150,000 common shares Prospectus supplement cover
Secondary offering Up to 2,815,256 common shares Prospectus supplement cover
Revenue $1.023 million Three months ended September 30, 2026; up 478% from $177,000 in 2025
Net loss $2.660 million Three months ended September 30, 2026; compared with $741,000 in 2025
Cash and cash equivalents $137,000 As of September 30, 2026
Accumulated deficit $111.655 million As of September 30, 2026
2026 equity purchase agreement commitment Up to $25.0 million Company may sell common stock over a 36-month period, subject to agreement conditions
Gross loss $363,000 loss Three months ended September 30, 2026; compared with $222,000 in 2025
real-world evidence medical
"for research, product development, regulatory submissions and real-world evidence generation"
Real-world evidence is information gathered from everyday sources like patient records, insurance claims, or everyday experiences, rather than controlled experiments or clinical trials. It helps investors understand how products or policies perform in real life, providing a more complete picture of their effectiveness and value beyond official tests. This type of evidence can influence decision-making by offering insights based on actual, everyday outcomes.
remaining performance obligations financial
"The Company’s remaining performance obligations consist of the delivery of contracted data units"
Remaining performance obligations are the work a company still needs to complete for its customers, like finishing a service or delivering a product. It’s important because it shows how much future income the company has coming in from current agreements, giving a clearer picture of its ongoing business.
Standby Equity Purchase Agreement financial
"entered into a Standby Equity Purchase Agreement (“2024 SEPA”) with YA II PN, LTD"
A standby equity purchase agreement is a contract in which an investor or group agrees to buy a company’s newly issued shares on demand, giving the company a ready source of cash it can tap when needed. Think of it like a line of credit made with stock instead of a loan: it provides financial backup but can increase the number of shares outstanding, diluting existing owners and affecting per‑share value, so investors watch these deals for their impact on ownership and earnings per share.
embedded put option financial
"includes an embedded put option and an embedded forward option"
anti-dilutive financial
"all potentially dilutive securities have been excluded from the computation"
A claim, security feature, or action described as anti-dilutive prevents or does not cause a reduction in existing shareholders’ per-share values when additional shares could be issued. For example, certain convertible securities or corporate actions are treated as anti-dilutive for earnings-per-share calculations if including them would raise EPS rather than lower it; investors watch this because it affects reported per-share metrics, ownership percentages, and valuation comparisons, like keeping pie slices the same size instead of making them smaller.
Level 1 inputs financial
"the end-of-day quoted price is both readily available and representative of fair value (Level 1 inputs)"
Offering Type mixed primary and secondary
Securities Offered Common stock
Offering Amount Primary offering: up to 1,150,000 shares; secondary offering: up to 2,815,256 shares

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares are in ONMD’s primary and secondary offerings?

The prospectus lists a primary offering of up to 1,150,000 common shares and a secondary offering of up to 2,815,256 common shares. Both amounts are described as common stock.

What are the limits on ONMD’s 2026 equity purchase agreement?

OneMedNet may, but is not obligated to, sell up to $25.0 million of common stock to Yorkville over 36 months. Sales are at the company’s option and subject to conditions, including effectiveness of a resale registration statement. Absent stockholder approval, issuances are capped at 19.9% of common stock outstanding as of July 1, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

Filed Pursuant to Rule 424(b)(3)

Registration No. 333-276130

 

Prospectus Supplement No. 7

(To Prospectus dated July 24, 2025)

 

 

Primary Offering of

Up to 1,150,000 Shares of Common Stock

 

Secondary Offering of

Up to 2,815,256 Shares of Common Stock

 

This prospectus supplement updates, amends and supplements the prospectus dated July 24, 2025 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-276130). Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the Prospectus.

 

This prospectus supplement is being filed to update, amend and supplement the information contained in the Prospectus with the information from our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, which was filed with the Securities and Exchange Commission on November 16, 2026 (the “Q3 2026 Form 10-Q”). Accordingly, we have attached the Q3 2026 Form 10-Q to this prospectus supplement.

 

This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference.

 

We are an “emerging growth company” as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company reporting requirements. Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 16 of the Prospectus for a discussion of information that should be considered in connection with an investment in our securities.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

 

The date of this prospectus is November 16, 2026.

 

 

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE TRANSITION PERIOD FROM TO

 

Commission File Number 001-40386

 

ONEMEDNET CORPORATION

(Exact name of Registrant as specified in its Charter)

 

Delaware   86-2076743

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

6385 Old Shady Oak Road, Suite 250

Eden Prairie, Minnesota

  55344
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (800) 918-7189

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, par value $0.0001 per share   ONMD   The Nasdaq Stock Market LLC
Redeemable Warrants, each lot of 10 warrants exercisable for one share of Common Stock at an exercise price of $115.00 per share   ONMDW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
       
Non-accelerated filer ☒ Smaller reporting company ☒
       
Emerging growth company ☒    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of November 16, 2026, there were 6,201,813 shares of common stock, par value $0.0001 per share, issued and outstanding.

 

 

 

 

 

 

Table of Contents

 

      Page
       
  CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS   ii
       
PART I. FINANCIAL INFORMATION    
       
Item 1. Condensed Consolidated Financial Statements   1
  Unaudited Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025   1
  Unaudited Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2026 and 2025   2
  Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Deficit for the three and nine months ended September 30, 2026 and 2025   3
  Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and 2025   5
  Notes to Unaudited Condensed Consolidated Financial Statements   6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations   19
Item 3. Quantitative and Qualitative Disclosures About Market Risk   27
Item 4. Controls and Procedures   27
       
PART II. OTHER INFORMATION    
       
Item 1. Legal Proceedings   28
Item 1A. Risk Factors   28
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds   29
Item 3. Defaults Upon Senior Securities   29
Item 4. Mine Safety Disclosures   29
Item 5. Other Information   29
Item 6. Exhibits   29
Signature   30

 

i

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

Certain statements that we make from time to time, including statements contained in this Quarterly Report on Form 10-Q (this “Report”) constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this Report are forward-looking statements. The forward-looking statements in this Report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. In some cases, you can identify these forward-looking statements by terms such as “anticipate,” “believe,” “continue,” “could,” “depends,” “estimate,” “expects,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms or other similar expressions, although not all forward-looking statements contain those words. These forward-looking statements are based on our current expectations and projections regarding future events and trends that may affect our financial condition, results of operations, strategy, business objectives, and financial needs.

 

Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Forward-looking statements in this Report include, without limitation, statements reflecting management’s expectations regarding future financial performance and operating expenditures (including our ability to continue as a going concern, to raise additional capital and to succeed in our future operations), expected growth, profitability and business outlook, liquidity, operating expenses, and enhancement of our internal control structure.

 

Forward-looking statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from those anticipated by such statements. These factors include, among other things, the unknown risks and uncertainties that we believe could cause actual results to differ from these forward looking statements as set forth under the heading, “Risk Factors” and elsewhere in this Report and other documents we file with the SEC. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all of the risks and uncertainties that could have an impact on the forward-looking statements, including without limitation, risks and uncertainties relating to:

 

  ● our projected financial position and estimated cash burn rate;
     
  ● our estimates regarding expenses, future revenues and capital requirements;
     
  ● our ability to continue as a going concern;
     
  ● our ability to raise substantial additional capital in sufficient amounts or on acceptable terms to fund our operations and our business plan;
     
  ● our ability to reverse the recent decline in our revenue and resume growing our revenue;
     
  ● our ability to obtain and maintain intellectual property protection for our current products and services;

 

ii

 

 

  ● our ability to protect our intellectual property rights and the potential for us to incur substantial costs from lawsuits to enforce or protect our intellectual property rights;
     
  ● the possibility that a third party may claim we have infringed, misappropriated or otherwise violated their intellectual property rights and that we may incur substantial costs and be required to devote substantial time defending against these claims;
  ● our reliance on third-party suppliers;
     
  ● the success of competing products or services that are or become available;
     
  ● our ability to expand our organization to accommodate potential growth and our ability to retain and attract key personnel;
     
  ● the potential for us to incur substantial costs resulting from lawsuits against us and the potential for these lawsuits to cause us to limit our commercialization of our products and services; and
     
  ● changes in demand for our products and services as a result of geopolitical and/or macroeconomic conditions.

 

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 and in other documents we file with the Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Report may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

 

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Report to conform these statements to actual results or to changes in our expectations.

 

You should read this Report and the documents that we incorporate by reference in this Form 10-Q with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements including those described in this Report and in the “Risk Factors” section of our Annual Report on Form 10-K and other documents we file with the Securities and Exchange Commission.

 

iii

 

 

PART I—FINANCIAL INFORMATION

 

Item 1. Condensed Consolidated Financial Statements

 

ONEMEDNET CORPORATION

 

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

 

    September 30, 2026     December 31, 2025  
    (unaudited)        
Assets                
Current assets:                
Cash and cash equivalents   $ 137     $ 585  
Investment in crypto assets – Bitcoin     -       506  
Accounts receivable, net     2,272       495  
Prepaid expenses and other current assets     156       509  
Total current assets     2,565       2,095  
Property and equipment, net     44       56  
Total assets   $ 2,609     $ 2,151  
Liabilities and stockholders’ deficit                
Current liabilities:                
Accounts payable and accrued expenses   $ 4,504     $ 3,496  
Deferred revenue     1,481       389  
Loans payable     464       754  
Advance from investor – related party     250       -  
2024 SEPA put option liability     -       186  
Total current liabilities     6,699       4,825  
2026 SEPA put option liability     436       -  
Loans payable, net of current portion     99       220  
Warrant liabilities     5       71  
Total liabilities     7,239       5,116  
Commitments and contingencies (Note 14)     -       -  
Stockholders’ deficit:                
Preferred Stock, par value $0.0001, 1,000,000 shares authorized at September 30, 2026 and December 31, 2025; no shares issued and outstanding at September 30, 2026 and December 31, 2025     -       -  
Common Stock, par value $0.0001, 100,000,000 shares authorized, 6,045,672 shares issued and 6,026,897 shares outstanding at September 30, 2026, and 5,198,464 shares issued and 5,179,689 shares outstanding at December 31, 2025     1       1  
Additional paid-in capital     107,553       101,933  
Treasury stock, at cost, 18,775 shares at September 30, 2026 and December 31, 2025     (529 )     (529 )
Accumulated deficit     (111,655 )     (104,370 )
Total stockholders’ deficit     (4,630 )     (2,965 )
Total liabilities and stockholders’ deficit   $ 2,609     $ 2,151  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

1

 

 

ONEMEDNET CORPORATION

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share data)

(Unaudited)

 

   2026   2025   2026   2025 
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2026   2025   2026   2025 
Revenue                    
Subscription revenue  $-   $-   $-   $105 
Data delivery revenue   1,023    177    1,410    363 
Total revenue   1,023    177    1,410    468 
Cost of revenue   1,386    399    2,928    1,136 
Gross margin   (363)   (222)   (1,518)   (668)
Operating expenses                    
General and administrative   1,185    1,386    3,439    3,999 
Sales and marketing   262    304    1,031    846 
Research and development   424    323    1,059    1,072 
Total operating expenses   1,871    2,013    5,529    5,917 
Loss from operations   (2,234)   (2,235)   (7,047)   (6,585)
Other expense (income), net                    
Interest expense   8    6    27    59 
Change in fair value of warrants   (19)   20    (66)   23 
Change in fair value of convertible notes   -    -    -    (1,285)
Change in fair value of crypto assets – Bitcoin   -    (55)   (147)   782 
Realized loss (gain) on sale of crypto assets – Bitcoin   -    (54)   234    (899)
Change in fair value of 2024 SEPA derivative liabilities   -    402    (245)   (32)
Change in fair value of 2026 SEPA derivative liabilities   436    -    436    - 
Gain on troubled debt restructurings   -    (1,862)   -    (5,569)
Loss on extinguishment of debt   -    41    -    41 
Other expense (income)   1    8    (1)   (44)
Total other expense (income), net   426    (1,494)   238    (6,924)
Net (loss) income  $(2,660)  $(741)  $(7,285)  $339 
Net (loss) income per share attributable to common shares – basic  $(0.43)  $(0.14)  $(1.25)  $0.08 
Weighted average shares of common stock outstanding – basic   6,148,636    5,261,803    5,837,487    4,125,372 
Net (loss) income per share attributable to common shares – diluted  $(0.43)  $(0.14)  $(1.25)  $0.08 
Weighted average shares of common stock outstanding – diluted   6,148,636    5,261,803    5,837,487    4,297,491 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

2

 

 

ONEMEDNET CORPORATION

 

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN

STOCKHOLDERS’ DEFICIT

(In thousands, except share data)

(Unaudited)

 

Three and Nine Months Ended September 30, 2026

 

   Shares   Amount   Shares   Amount   Capital   Deficit   Deficit 
           Additional       Total 
   Common Stock   Treasury Stock   Paid-in   Accumulated   Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Deficit 
Balances as of December 31, 2025   5,198,464   $1    (18,775)  $(529)  $101,933   $(104,370)  $(2,965)
Issuance of common stock in connection with 2024 SEPA   40,000    -    -    -    408    -    408 
Issuance of common stock in connection with subscription agreement with related party   59,524    -    -    -    500    -    500 
Stock-based compensation expense   -    -    -    -    431    -    431 
Net loss   -    -    -    -    -    (2,453)   (2,453)
Balances as of March 31, 2026   5,297,988    1    (18,775)   (529)   103,272    (106,823)   (4,079)
Issuance of common stock in connection with 2024 SEPA   95,387    -    -    -    495    -    495 
Issuance of common stock in connection with subscription agreements with related parties   194,321    -    -    -    1,550    -    1,550 
Conversion of officer accrued salary into shares of common stock   21,943    -    -    -    182    -    182 
Issuance of common stock in connection with exercise of pre-funded warrants   67,754    -    -    -    -    -    - 
Issuance of common stock in connection with exercise of warrants   13,310    -    -    -    43    -    43 
Vesting of restricted stock units   100,225    -    -    -    -    -    - 
Stock-based compensation expense   -    -    -    -    463    -    463 
Net loss   -    -    -    -    -    (2,172)   (2,172)
Balances as of June 30, 2026   5,790,928    1    (18,775)   (529)   106,005    (108,995)   (3,518)
Issuance of common stock in connection with subscription agreements with related parties   159,214    -    -    -    1,090    -    1,090 
Vesting of restricted stock units   95,530    -    -    -    -    -    - 
Stock-based compensation expense   -    -    -    -    458    -    458 
Net loss   -    -    -    -    -    (2,660)   (2,660)
Balances as of September 30, 2026   6,045,672   $1    (18,775)  $(529)  $107,553   $(111,655)  $(4,630)

 

3

 

 

Three and Nine Months Ended September 30, 2025

 

           Additional       Total 
   Common Stock   Treasury Stock   Paid-in   Accumulated   Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Deficit 
Balances as of December 31, 2024   2,817,528   $1    (18,775)  $(529)  $86,147   $(101,569)  $(15,950)
Issuance of common stock in connection with September 2024 private placement   147,370    -    -    -    -    -    - 
Issuance of common stock upon partial conversion of Yorkville Note   111,171    -    -    -    1,094    -    1,094 
Stock-based compensation expense   -    -    -    -    208    -    208 
Net loss   -    -    -    -    -    (1,902)   (1,902)
Balances as of March 31, 2025   3,076,069    1    (18,775)   (529)   87,449    (103,471)   (16,550)
Issuance of common stock in connection with settlement of vendor payable   25,000    -    -    -    111    -    111 
Issuance of common stock upon partial conversion of Yorkville Note   75,486    -    -    -    298    -    298 
Issuance of common stock upon conversion of loans with related parties   316,648    -    -    -    2,334    -    2,334 
Issuance of common stock upon conversion of PIPE Notes   145,318    -    -    -    510    -    510 
Issuance of common stock upon conversion of loan extensions with related parties   365,025    -    -    -    2,584    -    2,584 
Issuance of common stock in connection with June 2025 private placement   339,093    -    -    -    2,497    -    2,497 
                                    
Issuance of common stock in connection with subscription agreements with related parties   285,715    -    -    -    1,197    -    1,197 
Stock-based compensation expense   -    -    -    -    197    -    197 
Net income   -    -    -    -    -    2,982    2,982 
                                    
Balances as of June 30, 2025   4,628,354    1    (18,775)   (529)   97,177    (100,489)   (3,840)
Balance   4,628,354    1    (18,775)   (529)   97,177    (100,489)   (3,840)
Issuance of common stock in connection with pre-funded warrant exercises   304,824    -    -    -    -    -    - 
Issuance of common stock in connection with subscription agreement with related party   58,140    -    -    -    500    -    500 
Stock-based compensation expense   -    -    -    -    142    -    142 
Net loss   -    -    -    -    -    (741)   (741)
Net income (loss)   -    -    -    -    -    (741)   (741)
Balances as of September 30, 2025   4,991,318   $1    (18,775)  $(529)  $97,819   $(101,230)  $(3,939)
Balance   4,991,318   $1    (18,775)  $(529)  $97,819   $(101,230)  $(3,939)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

4

 

 

ONEMEDNET CORPORATION

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

   2026   2025 
   Nine Months Ended September 30, 
   2026   2025 
Cash flows from operating activities:          
Net (loss) income  $(7,285)  $339 
Adjustments to reconcile net (loss) income to net cash used in operating activities:          
Depreciation and amortization   24    56 
Stock-based compensation expense   1,352    547 
Change in fair value of warrants   (66)   23 
Change in fair value of convertible notes   -    (1,285)
Change in fair value of crypto assets – Bitcoin   (147)   782 
Change in fair value of 2024 SEPA derivative liabilities   (245)   (32)
Change in fair value of 2026 SEPA derivative liabilities   436    - 
Realized loss (gain) on sale of crypto assets – Bitcoin   234    (899)
Gain on troubled debt restructurings   -    (5,569)
Loss on extinguishment of debt   -    41 
Non-cash interest   -    45 
Change in operating assets and liabilities:          
Accounts receivable   (1,777)   (369)
Prepaid expenses and other current assets   353    270 
Accounts payable and accrued expenses   1,190    387 
Deferred revenue   1,092    209 
Net cash used in operating activities   (4,839)   (5,455)
Cash flows from investing activities:          
Purchases of property and equipment   (12)   (8)
Purchases of crypto assets – Bitcoin   -    (2,400)
Sales of crypto assets – Bitcoin   419    4,766 
Net cash provided by investing activities   407    2,358 
Cash flows from financing activities:          
Proceeds from 2024 SEPA   962    - 
Proceeds from subscription agreements with related parties   3,140    1,697 
Proceeds from investor advance – related party   250    - 
Proceeds from exercise of warrants   43    - 
Proceeds from private placement   -    2,497 
Repayment of Yorkville Note   -    (262)
Repayment of deferred underwriter fees payable   -    (500)
Repayment of loans payable   (411)   (358)
Net cash provided by financing activities   3,984    3,074 
Net decrease in cash and cash equivalents   (448)   (23)
Cash and cash equivalents at beginning of period   585    172 
Cash and cash equivalents at end of period  $137   $149 
Supplemental disclosures of cash flow information:          
Cash paid for interest  $27   $33 
Cash paid for taxes  $1   $- 
Supplemental disclosures of non-cash investing and financing activities:          
Conversion of officer accrued salary into shares of common stock  $182   $- 
Issuance of common stock in connection with settlement of vendor payable  $-   $111 
Issuance of common stock upon conversion of convertible notes  $-   $1,902 
Issuance of common stock upon conversion of loans with related parties  $-   $2,334 
Issuance of common stock upon conversion of loan extensions with related parties  $-   $2,584 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

5

 

 

ONEMEDNET CORPORATION

 

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

1. Description of Business

 

Organization and Description of Business

 

OneMedNet Corporation (the “Company”) is a healthcare technology company focused on the acquisition, curation, de-identification and commercialization of real-world clinical data. Through its proprietary iRWD™ platform and network of healthcare providers, the Company provides pharmaceutical companies, medical device manufacturers, contract research organizations, academic institutions and artificial intelligence developers with access to longitudinal, multimodal clinical datasets for use in research, product development, regulatory submissions and real-world evidence generation.

 

The Company’s platform identifies, de-identifies and curates clinical data obtained from healthcare providers, including electronic health records, clinical notes, medical imaging, laboratory results and other clinical information. The Company combines its technology, healthcare provider network and clinical expertise to develop fit-for-purpose datasets based on customer-specific requirements.

 

The Company was incorporated in Delaware on November 20, 2015 and is headquartered in Eden Prairie, Minnesota. The Company has one wholly owned subsidiary, OneMedNet Technologies (Canada) Inc., incorporated under the Business Corporations Act (British Columbia).

 

On November 7, 2023, Data Knights Merger Sub, Inc., a wholly owned subsidiary of Data Knights Acquisition Corp., merged with and into OneMedNet Solutions Corporation (formerly named OneMedNet Corporation), with OneMedNet Solutions Corporation surviving as a wholly owned subsidiary. Following the consummation of the transaction, Data Knights Acquisition Corp. was renamed OneMedNet Corporation.

 

Basis of Presentation and Consolidation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules and regulations, certain notes or other financial information normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal, recurring adjustments that are necessary to present fairly the Company’s results for the interim periods presented. The results from operations for the three and nine months ended September 30, 2026 are not necessarily indicative of the results to be expected for the year ending December 31, 2026, or for any future annual or interim period.

 

The accompanying interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes for the year ended December 31, 2025 in the Company’s Annual Report on Form 10-K, filed with the SEC on March 30, 2026 (the “Form 10-K”).

 

The interim unaudited condensed consolidated financial statements include the consolidated accounts of the Company’s wholly owned subsidiary, OneMedNet Technologies (Canada) Inc. All significant intercompany transactions have been eliminated in consolidation.

 

Reverse Stock Split

 

At the Company’s 2026 annual meeting of stockholders held on September 18, 2026, the Company’s stockholders approved a proposal to effect a reverse stock split of the Company’s common stock by a ratio ranging from any whole number between 1-for-5 and 1-for-20, as determined by the Board of Directors in its discretion.

 

On September 29, 2026, the Company effected a 1-for-10 reverse stock split of the Company’s common stock, par value $0.0001 per share (“Common Stock”) (the “Reverse Stock Split”). As a result of the Reverse Stock Split, every 10 shares of the Company’s Common Stock issued and outstanding were automatically converted into one new share of Common Stock. Proportionate adjustments were also made to the number of shares available under the Company’s equity incentive plans and the exercise price and number of shares underlying outstanding restricted stock units, warrants, and other equity awards. The Reverse Stock Split did not decrease the number of authorized shares of Common Stock and preferred stock or otherwise affect the par value of the Common Stock. No fractional shares were issued in connection with the Reverse Stock Split and any fractional shares resulting from the Reverse Stock Split were rounded up to the nearest whole share for stockholders of record who would be entitled to receive fractional shares pursuant to the Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of the Company effecting the Reverse Stock Split..

 

All information presented herein, unless otherwise indicated herein, reflects the Reverse Stock Split of the Company’s outstanding shares of common stock, and unless otherwise indicated, all such amounts and corresponding conversion price or exercise price data set forth herein have been adjusted to give effect to such Reverse Stock Split.

 

Liquidity and Going Concern

 

The Company has incurred recurring net losses since its inception, including $2.7 million and $0.7 million for the three months ended September 30, 2026 and 2025, respectively. In addition, the Company had an accumulated deficit of $111.7 million as of September 30, 2026. The Company’s cash balance of $0.1 million is not adequate to fund its operations through at least 12 months from the date these condensed consolidated financial statements were issued. Therefore, these conditions raise substantial doubt about the Company’s ability to continue as a going concern.

 

6

 

 

To continue and expand its operations, the Company will be required to, and management plans to, raise additional working capital through equity or debt offerings and ultimately hopes to attain profitable operations to fulfill its operating and capital requirements for at least 12 months from the date of the issuance of the condensed consolidated financial statements. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to raise capital and to achieve positive cash flow from operations.

 

Risks and Uncertainties

 

The Company is subject to risks common to companies in the markets it serves, including, but not limited to, global economic and financial market conditions, fluctuations in customer demand, acceptance of new products, development by its competitors of new technological innovations, dependence on key personnel, and protection of proprietary technology.

 

In addition, the Company has previously invested in Bitcoin, which is a crypto asset. Crypto assets are loosely regulated and there is no central marketplace for currency exchange. Supply is determined by a computer code, not by a central bank, and prices have been extremely volatile. Certain crypto asset exchanges have been closed due to fraud, failure or security breaches. Any of the Company’s crypto assets that reside on an exchange that shuts down may be lost. Several factors may affect the price of crypto assets, including, but not limited to: supply and demand, investors’ expectations with respect to the rate of inflation, interest rates, currency exchange rates or future regulatory measures (if any) that restrict the trading of crypto assets, and the use of crypto assets as a form of payment. There is no assurance that crypto assets will maintain their long-term value in terms of purchasing power in the future, or that acceptance of crypto asset payments by mainstream retail merchants and commercial businesses will continue to grow.

 

As crypto assets have grown in popularity and market size, various countries and jurisdictions have begun to develop regulations governing the crypto asset industry. To the extent future regulatory actions or policies limit the ability to exchange crypto assets or utilize them for payments, the demand for crypto assets could be reduced. Furthermore, regulatory actions may limit the ability of end-users to convert crypto assets into fiat currency (e.g., U.S. dollars) or use crypto assets to pay for goods and services. Such regulatory actions or policies could result in a reduction of demand, and in turn, a decline in the underlying crypto asset unit prices.

 

The effect of any future regulatory change on crypto assets in general is impossible to predict, but such change could be substantial and adverse to the Company and the value of the Company’s investments in crypto assets.

 

Crypto assets are not insured or protected under the Federal Deposit Insurance Corporation (“FDIC”) or the Securities Investor Protection Corporation (“SIPC”). Accordingly, with respect to its historical Bitcoin investment, the Company did not enjoy the protections of other assets covered by the FDIC or SIPC. As of September 30, 2026, the Company no longer held any Bitcoin or other crypto assets.

 

2. Summary of Significant Accounting Policies

 

Except as described below, the accounting policies of the Company are set forth in Note 2 to the consolidated financial statements contained in the Form 10-K, and the accounting policies followed by the Company for interim financial reporting are consistent with the accounting policies therein.

 

7

 

 

Reclassification

 

Certain prior period amounts have been reclassified to conform to the current year presentation. These reclassifications had no impact on the Company’s net loss, net cash flows, or stockholders’ deficit.

 

Accounting Pronouncements Not Yet Adopted

 

In November 2024, the FASB issued ASU 2024-03, Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), which requires public entities, at annual and interim reporting periods, to disclose in a tabular format additional information about specific expense categories in the notes to the consolidated financial statements. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03 on the presentation of its condensed consolidated financial statements and footnotes.

 

The Company has reviewed other recently issued accounting pronouncements and concluded that either they are not applicable to the business or no material effect is expected upon future adoption.

 

3. Segment Information

 

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (“CODM”), or decision-making group, in deciding how to allocate resources and in assessing performance. The Company considers its chief executive officer to be the Company’s CODM. The CODM manages its operations and allocates resources based on the Company’s consolidated results and therefore operates as one segment.

 

The Company’s operations consist of its real-world data (“RWD”) platform, which enables life sciences and healthcare customers to access curated clinical and imaging datasets. The Company decommissioned its legacy BEAM platform in May 2025 as part of its strategic transition to a unified real-world data platform. Revenue associated with the BEAM platform was generated through the date of decommissioning and will not continue in future periods.

 

The Company’s method for measuring segment profitability is operating loss, which the CODM uses to assess performance and make decisions for resource allocation, consistent with the measurement principles for operating loss as reported on the Company’s condensed consolidated statements of operations. The CODM uses consolidated operating loss to set budgets, evaluate margins, review actual results, and to make decisions whether to engage in capital management transactions.

 

The significant expenses regularly reviewed by the CODM are consistent with those reported on the Company’s condensed consolidated statements of operations, and expenses are not regularly reviewed on a more disaggregated basis for purposes of assessing segment performance and deciding how to allocate resources.

 

The Company’s disaggregation of revenue by major product offering is consistent with its presentation on the Company’s condensed consolidated statements of operations. See Note 4 for revenue by geographic location.

 

8

 

 

4. Revenue

 

The Company’s disaggregation of revenue by major product offering is consistent with its presentation on the condensed consolidated statements of operations. Data delivery revenue is recognized at a point in time. Subscription revenue, which ceased following the decommissioning of the BEAM platform in May 2025, was recognized over time. The following table presents revenue by geographic region, based on the location of the customer (in thousands):

 Schedule of Revenue by Geographic Region

   2026   2025   2026   2025 
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2026   2025   2026   2025 
Americas  $919   $99   $1,051   $272 
Rest of World   104    78    359    196 
Total  $1,023   $177   $1,410   $468 

 

Contract Balances

 

Accounts receivable, net includes unbilled receivables of $0.9 million and $0.2 million as of September 30, 2026 and December 31, 2025, respectively. The Company had no allowance for credit losses as of September 30, 2026 or December 31, 2025, and there was no activity in the allowance during the three and nine months ended September 30, 2026 and 2025. Unbilled receivables arise when data delivery revenue is recognized before the customer is invoiced and the Company’s right to consideration is unconditional, such that only the passage of time is required before payment is due. The Company had no contract assets as of September 30, 2026 or December 31, 2025.

 

Deferred revenue consists of amounts invoiced or received before data is delivered to and accepted by the customer and is recognized as revenue upon the customer’s acceptance of the data. The increase in deferred revenue from December 31, 2025 to September 30, 2026 was primarily due to advance billings under iRWD contracts for which data had not been delivered as of September 30, 2026. The beginning deferred revenue balances as of December 31, 2025 and December 31, 2024 were $0.4 million and $0.6 million, respectively. During the nine months ended September 30, 2026 and 2025, the Company recognized revenue of $0.1 million and $0.2 million, respectively, that was included in deferred revenue at the beginning of the respective periods.

 

Remaining Performance Obligations

 

The Company’s remaining performance obligations consist of the delivery of contracted data units under iRWD contracts, which are recognized as revenue upon the customer’s acceptance of the data. The Company has elected the practical expedient in ASC 606-10-50-14 not to disclose the value of remaining performance obligations for contracts with an original expected duration of one year or less. For the remaining contracts, the aggregate amount of transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied and expected to be recognized beyond 12 months is not material.

 

Customer Concentration

 

For the three and nine months ended September 30, 2026, three customers each accounted for 10% or more of total revenue, together representing 81% and 59% of total revenue, respectively. The largest customer represented 54% and 39% of total revenue for the respective periods. As of September 30, 2026, two customers each accounted for 10% or more of accounts receivable, net, together representing 44% of the total balance. As of December 31, 2025, three customers each accounted for 10% or more of accounts receivable, net, together representing 51% of the total balance. The loss of, or a significant reduction in business from, any of these customers could have a material adverse effect on the Company’s results of operations, financial condition, and liquidity.

 

For the three and nine months ended September 30, 2025, five and two customers, respectively, each accounted for 10% or more of total revenue, together representing 76% and 26% of total revenue, respectively.

 

9

 

 

5. Crypto Assets Held

 

The Company’s crypto assets are comprised solely of Bitcoin. In accordance with ASC Topic 820, Fair Value Measurement, the Company measures the fair value of its Bitcoin based on the quoted end-of-day price on the measurement date for a single Bitcoin on an active trading platform, River.com. Management has determined that River.com, an active exchange market, represents a principal market for Bitcoin and the end-of-day quoted price is both readily available and representative of fair value (Level 1 inputs). The following table sets forth the units held, cost basis, and fair value of its investments in crypto assets, as shown on the condensed consolidated balance sheets as of December 31, 2025 (in thousands):

Schedule of Crypto Assets Held 

   December 31, 2025 
   Units   Cost Basis   Fair Value 
Crypto assets held:               
Bitcoin   6   $653   $506 
Total   6   $653   $506 

 

There were no crypto assets held by the Company as of September 30, 2026.

 

The following table presents a reconciliation of the fair values of the Company’s investments in crypto assets for the nine months ended September 30, 2026 (in thousands):

 Schedule of Crypto Assets Reconciliation of Fair Values

   Bitcoin 
Balance, December 31, 2025  $506 
Dispositions   (653)
Unrealized gain, net   147 
Balance, September 30, 2026  $- 

 

For the nine months ended September 30, 2026, the Company had Bitcoin dispositions of $0.7 million (including realized loss of $0.2 million). There was no Bitcoin activity for the three months ended September 30, 2026. Dispositions are the result of sales of Bitcoin. The Company uses a first-in, first-out methodology to assign costs to Bitcoin for purposes of the Bitcoin held and realized gains and losses disclosure above. Bitcoin is included in current assets in the condensed consolidated balance sheets due to the Company’s ability to sell them in a highly liquid marketplace and its intent to liquidate its Bitcoin to support operations when needed.

 

6. Accounts Payable and Accrued Expenses

 

Accounts payable and accrued expenses consisted of the following (in thousands):

 Schedule of Accounts Payable and Accrued Expenses

   September 30, 2026   December 31, 2025 
   As of 
   September 30, 2026   December 31, 2025 
Professional fees  $1,779   $1,611 
Software and technology   1,223    682 
Payroll liabilities   538    730 
Data provider costs   868    356 
Other   96    117 
Total  $4,504   $3,496 

 

10

 

 

In April 2026, the Company issued 21,943 shares of its Common Stock at a price of $8.30 per share in exchange for the settlement of approximately $0.2 million of unpaid cash salary due to an officer and related party investor of the Company. The transaction was accounted for as a capital transaction with a related party and no gain or loss was recognized. As such, the net carrying value of $0.2 million was reclassified to stockholders’ deficit in the condensed consolidated balance sheets at the time of the conversion.

 

7. Debt

 

The following table summarizes outstanding debt for the periods indicated (in thousands):

 Schedule of Outstanding Debt

   September 30, 2026   December 31, 2025 
   As of 
   September 30, 2026   December 31, 2025 
Loans payable          
Stock repurchase loan  $125   $118 
Insurance premium loan   -    286 
Extension loans   339    350 
Loans payable   464    754 
Long-term loans payable          
Extension loans   -    26 
Stock repurchase loan   99    194 
Long- term loans payable   99    220 
Total  $563   $974 

 

8. Stockholders’ Deficit

 

2024 SEPA Draws

 

As further described in the Form 10-K, the Company entered into a Standby Equity Purchase Agreement (“2024 SEPA”) with YA II PN, LTD, a Cayman Islands exempt limited company (“Yorkville”), on June 17, 2024. Under the 2024 SEPA, the Company has the right to sell to Yorkville up to $25.0 million of its Common Stock, subject to certain limitations and conditions set forth in the 2024 SEPA, from time to time, over a 24-month period. The 2024 SEPA was accounted for as a liability under ASC 815 as it includes an embedded put option and an embedded forward option. The put option is recognized at inception and the forward option is recognized upon issuance of notice for the sale of the Company’s Common Stock.

 

The commitment period under the 2024 SEPA expired in June 2026 and, therefore, the derivative liability was $0 at September 30, 2026. The fair value of the derivative liability related to the embedded put option was estimated at $0.2 million at December 31, 2025, which was classified within short-term liabilities on the condensed consolidated balance sheets because the commitment period expires in less than one year.

 

During the nine months ended September 30, 2026, the Company delivered four advance notices for the sale of 135,387 shares of its Common Stock, resulting in cumulative gross proceeds of $1.0 million. A derivative asset for each embedded forward option was initially recorded at fair value upon delivery of each advance notice, which was subsequently remeasured with changes in fair value recorded in the condensed consolidated statements of operations until settlement. The Company recognized a gain of $0.1 million related to embedded forward options during the nine months ended September 30, 2026. The embedded forward option was deemed to have no value at December 31, 2025 as there were no outstanding notices for the sale of the Company’s Common Stock. During the nine months ended September 30, 2025, the Company did not deliver any advance notices under the 2024 SEPA.

 

The estimated issuance date fair value and remeasurement adjustments for the embedded put and forward options are presented within other expense (income), net under the caption change in fair value of 2024 SEPA derivative liabilities in the accompanying condensed consolidated statements of operations. The embedded put option resulted in a fair value gain of $0.2 million for the nine months ended September 30, 2026, a fair value loss of $0.4 million for the three months ended September 30, 2025, and a fair value gain of $0.03 million for the nine months ended September 30, 2025. The embedded forward option resulted in a fair value gain of $0.1 million for the nine months ended September 30, 2026, with no fair value adjustment for the three or nine months ended September 30, 2025. There was no activity under the 2024 SEPA during the three months ended September 30, 2026, as the facility expired in June 2026.

 

11

 

 

2026 SEPA

 

On July 1, 2026, the Company entered into a separate standby equity purchase agreement (the “2026 SEPA”) with Yorkville. Under the 2026 SEPA, the Company has the right, but not the obligation, to sell to Yorkville up to $25.0 million of its Common Stock, subject to certain limitations and conditions set forth in the 2026 SEPA, from time to time over a 36-month period. Sales of Common Stock to Yorkville under the 2026 SEPA, and the timing of any such sales, are at the Company’s option.

 

Upon satisfaction of the conditions set forth in the 2026 SEPA, including the effectiveness of a resale registration statement covering the applicable shares, the Company may direct Yorkville to purchase a specified number of shares of Common Stock by delivering written notice (each, an “Advance”). An Advance may not exceed the greater of (i) 50,000 shares of Common Stock (as adjusted for the Reverse Stock Split) and (ii) 100% of the average daily trading volume of the Common Stock during the five trading days immediately preceding the Advance.

 

Yorkville will generally purchase shares pursuant to an Advance at a price per share equal to 97% of the Market Price, as defined in the 2026 SEPA. The Company may establish a minimum acceptable price for each Advance, below which the Company will not be obligated to sell shares to Yorkville.

 

The 2026 SEPA limits the number of shares that may be sold to Yorkville such that Yorkville and its affiliates may not beneficially own more than 4.99% of the Company’s outstanding voting power or number of shares of Common Stock. In addition, absent stockholder approval, the issuance of Common Stock under the 2026 SEPA is capped at 19.9% of the Company’s outstanding Common Stock as of July 1, 2026.

 

The 2026 SEPA will automatically terminate on the earlier of (i) the 36-month anniversary of the agreement or (ii) the date on which Yorkville has made payments for shares of Common Stock equal to the $25.0 million commitment amount. The Company may also terminate the 2026 SEPA upon five trading days’ prior written notice, subject to the conditions specified in the agreement.

 

The 2026 SEPA was accounted for as a liability under ASC 815 as it includes an embedded put option and an embedded forward option. The put option is recognized at inception and the forward option is recognized upon issuance of notice for the sale of the Company’s Common Stock.

 

The fair value of the derivative liability related to the embedded put option was estimated at $0.5 million at the inception of the agreement and $0.4 million as of September 30, 2026. The estimated issuance date fair value and remeasurement adjustment for the embedded put option is presented as a single line within other (income) expense, net in the accompanying condensed consolidated statements of operations under the caption change in fair value of 2026 SEPA derivative liabilities. The embedded forward option was deemed to have no value at September 30, 2026 as there were no outstanding notices for the sale of the Company’s Common Stock.

 

Subscription Agreements – Related Parties

 

Between February and September 2026, the Company entered into subscription agreements with two related party investors pursuant to which the Company agreed to issue and sell an aggregate of 413,059 shares of its Common Stock at prices between $5.80 and $9.30 per share. The Company received gross proceeds of approximately $3.1 million from the related party subscription agreements.

 

In October 2026, the Company issued 129,758 shares of common stock to a related party investor at a purchase price of $5.78 per share for aggregate proceeds of $0.8 million. The Company had received $0.3 million of the aggregate proceeds prior to September 30, 2026, which was recorded as a liability as of September 30, 2026, with the remaining $0.5 million received upon closing in October 2026.

 

ARC Forward Contract

 

As of September 30, 2026 and December 31, 2025, the Company had an outstanding forward contract to issue 124,065 shares of its Common Stock to ARC Group Limited for success fees earned from Data Knights in connection with the Business Combination. The forward contract was included in additional paid-in-capital in stockholders’ deficit in the condensed consolidated balance sheets as it met the criteria for equity accounting under ASC 815.

 

9. Net (Loss) Income per Share

 

Basic and diluted net (loss) income per share was calculated as follows:

 Schedule of Basic and Diluted Net Income (Loss) per Share

   2026   2025   2026   2025 
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2026   2025   2026   2025 
Numerator:                    
Net (loss) income  $(2,660)  $(741)  $(7,285)  $339 
Less: undistributed earnings attributable to participating warrant holders   -    -    -   $(35)
Net (loss) income attributable to common shareholders – basic  $(2,660)  $(741)  $(7,285)  $304 
Reallocation of undistributed earnings attributable to participating warrant holders   -   $-    -    1 
Net (loss) income attributable to common shareholders – diluted  $(2,660)  $(741)  $(7,285)  $305 
Denominator:                    
Weighted average shares of common stock outstanding – basic   6,148,636    5,261,803    5,837,487    4,125,372 
Net (loss) income per share attributable to common shares – basic  $(0.43)  $(0.14)  $(1.25)  $0.08 
Effect of dilutive securities                    
Restricted stock units   -    -    -    125,719 
Warrants   -    -    -    6,404 
Loan extensions   -    -    -    39,996 
Dilutive potential common shares   -    -    -    172,119 
Weighted average shares of common stock outstanding – diluted   6,148,636    5,261,803    5,837,487    4,297,491 
Net (loss) income per share attributable to common shares – diluted  $(0.43)  $(0.14)  $(1.25)  $0.08 

 

12

 

 

For the three and nine months ended September 30, 2026, and three months ended September 30, 2025, during which the Company recorded a net loss, all potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share, and thus they are considered “anti-dilutive.” For these periods, the weighted average number of shares of Common Stock outstanding used to calculate both basic and diluted net loss per share of common stock is the same.

 

For the nine months ended September 30, 2025, the Company reported net income. For this period, net income is allocated to the participating warrants and the Common Stock based on their participation rights. Under the two-class method, basic net income per share is computed by dividing net income attributable to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period. In addition, the dilutive effect of restricted stock units and warrants were calculated using the treasury stock method, whereby all such awards were assumed to be exercised at the beginning of the period. The hypothetical proceeds from such exercises, including the average unrecognized stock compensation expense for restricted stock units, were assumed to be used to purchase outstanding Common Stock at the average price during the period. The net share impact of dilutive securities was added to the weighted average basic common shares outstanding to calculate weighted average diluted shares outstanding.

 

The Company excluded the following potential shares of Common Stock, presented based on amounts outstanding at each period end, from the computation of diluted net (loss) income per share for the periods indicated because including them would have had an anti-dilutive effect:

 Schedule of Antidilutive Earnings Per Share

   2026   2025   2026   2025 
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2026   2025   2026   2025 
Restricted stock units   326,955    185,010    326,955    59,292 
Warrants for Common Stock   1,352,845    1,236,412    1,352,845    1,230,008 
Extension loans   -    34,087    -    - 
Total common stock equivalents   1,679,800    1,455,509    1,679,800    1,289,300 

 

10. Stock-Based Compensation

 

The Company recorded stock-based compensation expense in the following categories on the accompanying condensed consolidated statements of operations for the periods presented (in thousands):

 Schedule of Stock-Based Compensation

    2026     2025     2026     2025  
    Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
Cost of revenue   $ 23     $ 4     $ 57     $ 12  
General and administrative     331       132       1,026       518  
Sales and marketing     44       1       131       4  
Research and development     60       5       138       13  
Total stock-based compensation expense   $ 458     $ 142     $ 1,352     $ 547  

 

11. Stock Warrants

 

The Company has the following warrants outstanding for the periods presented:

 

 Schedule of Warrants Outstanding

    September 30, 2026     December 31, 2025  
    As of  
    September 30, 2026     December 31, 2025  
Liability Classified Warrants                
Business Combination Warrants     58,528       58,528  
PIPE Warrants     9,575       9,575  
Subtotal     68,103       68,103  
Equity Classified Warrants                
Public Warrants     1,150,000       1,150,000  
Private Placement Warrants     134,742       215,807  
Subtotal     1,284,742       1,365,807  
Grand Total     1,352,845       1,433,910  
Warrants outstanding     1,352,845       1,433,910  

 

13

 

 

On June 30, 2026, the Company issued 67,754 shares of Common Stock upon the partial exercise of pre-funded warrants and 13,310 shares of Common Stock upon the full exercise of warrants, both of which were originally issued in September 2024. The warrant exercise generated cash proceeds of approximately $0.04 million. As of September 30, 2026, no warrants or pre-funded warrants issued in connection with the September 2024 financing remained outstanding.

 

12. Fair Value Measurements

 

The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis, inclusive of related party (in thousands):

 Schedule of Assets and Liabilities Measured at Fair Value

   Level 1   Level 2   Level 3   Total 
   September 30, 2026 
   Level 1   Level 2   Level 3   Total 
Assets:                    
Money market funds  $35   $-   $-   $35 
Total assets, at fair value  $35   $-   $-   $35 
Liabilities:                    
Business Combination Warrants  $-   $-   $2   $2 
PIPE Warrants   -    -    3    3 
2026 SEPA put option liability   -    -    436    436 
Total liabilities, at fair value  $-   $-   $441   $441 

 

   Level 1   Level 2   Level 3   Total 
   December 31, 2025 
   Level 1   Level 2   Level 3   Total 
Assets:                    
Money market funds  $35   $-   $-   $35 
Bitcoin   506    -    -    506 
Total assets, at fair value  $541   $-   $-   $541 
Liabilities:                    
Business Combination Warrants  $-   $-   $60   $60 
PIPE Warrants   -    -    11    11 
2024 SEPA put option liability   -    -    186    186 
Total liabilities, at fair value  $-   $-   $257   $257 

 

Business Combination Warrants and PIPE Warrants

 

The following table presents the changes in the Business Combination Warrants and PIPE Warrants measured at fair value during the three and nine months ended September 30, 2026 (in thousands):

 Schedule of Warrants and Notes Measured at Fair Value

  

Business

Combination

Warrants

   PIPE Warrants 
Balance, December 31, 2025  $60   $11 
Changes in fair value   (14)   (2)
Balance, March 31, 2026  $46   $9 
Changes in fair value   (26)   (5)
Conversions to Common Stock          
Balance, June 30, 2026  $20   $4 
Changes in fair value   (18)   (1)
Balance, September 30, 2026  $2   $3 

 

14

 

 

The Company remeasured the fair value of the Business Combination Warrants and PIPE Warrants at September 30, 2026 using the Black-Scholes option-pricing model with the following assumptions:

 Schedule of Fair Value Assumptions and Valuation

   Warrants   Warrants 
   As of September 30, 2026 
   PIPE   Business Combination 
   Warrants   Warrants 
Stock price  $5.79   $5.79 
Exercise price  $100.00   $115.00 
Expected volatility   103.5%   103.5%
Weighted average risk-free rate   4.8%   4.8%
Expected dividend yield   0.0%   0.0%
Expected term (in years)   2.1    2.1 

 

The Company remeasured the fair value of the Business Combination Warrants and PIPE Warrants at December 31, 2025 using the Black-Scholes option-pricing model with the following assumptions:

 

   Warrants   Warrants 
   As of December 31, 2025 
   PIPE   Business
Combination
 
   Warrants   Warrants 
Stock price  $11.00   $11.00 
Exercise price  $100.00   $115.0 
Expected volatility   85.0%   85.0%
Weighted average risk-free rate   3.5%   3.5%
Expected dividend yield   0.0%  0.0%
Warrants measurement input   0.0%   0.0%
Expected term (in years)   2.85    2.85 

 

2024 SEPA Derivative Liability

 

The 2024 SEPA expired in June 2026. The following table presents the changes in the 2024 SEPA derivative liabilities measured at fair value during the nine months ended September 30, 2026 (in thousands):

 

    2024 SEPA Put Option     2024 SEPA Forward Option  
Balance, December 31, 2025   $ 186     $ -  
Changes in fair value     (186 )     (59 )
Conversions to Common Stock     -       59  
Balance, September 30, 2026   $ -     $ -  

 

The estimated fair value of the 2024 SEPA put option derivative liability was determined using a Monte Carlo simulation model in order to project the future path of the Company’s stock price over the commitment period with the following assumptions at December 31, 2025:

 

    As of  
    December 31, 2025  
Term (in years)     0.5  
Starting stock price   $ 11.0  
Expected volatility     144.0 %
Risk-free rate     3.6 %
         
Risk-free rate     3.6 %

 

15

 

 

The 2024 SEPA forward option liability was deemed to have no value at December 31, 2025 as there were no outstanding notices for the sale of the Company’s Common Stock.

 

The commitment period under the 2024 SEPA expired in June 2026, therefore, the 2024 SEPA derivative liability balances were $0 at September 30, 2026.

 

2026 SEPA Derivative Liability

 

The following table presents the changes in the 2026 SEPA derivative liabilities measured at fair value during the nine months ended September 30, 2026 (in thousands):

 Schedule of Warrants and Notes Measured at Fair Value

    2026 SEPA Put Option  
Balance, December 31, 2025   $ -  
Additions     478  
Changes in fair value     (42 )
Balance, September 30, 2026   $ 436  

 

The estimated fair value of the 2026 SEPA put option derivative liability was determined using a Monte Carlo simulation model in order to project the future path of the Company’s stock price over the commitment period with the following assumptions at September 30, 2026:

Schedule of Fair Value Assumptions and Valuation 

   As of 
   September 30, 2026 
Term (in years)   2.8 
Starting stock price  $5.79 
Expected volatility   141.8%
Risk-free rate   4.9%
Derivative liability   4.9%

 

16

 

 

The 2026 SEPA forward option liability was deemed to have no value at September 30, 2026 as there were no outstanding notices for the sale of the Company’s Common Stock.

 

13. Related Party Transactions

 

Conversion of Officer Accrued Salary – As described in Note 6, the Company issued 21,943 shares of Common Stock in exchange for the settlement of approximately $0.2 million of unpaid cash salary due to an officer and related party investor of the Company. See Note 6 for further details.

 

Subscription Agreements – As described in Note 8, the Company issued 413,059 shares of Common Stock in exchange for gross proceeds of $3.1 million pursuant to subscription agreements with two related party investors between February and September 2026. See Note 8 for further details.

 

In September 2026, the Company also received a $0.3 million advance from a related party investor in connection with a subscription for shares of Common Stock completed in October 2026. The advance was recorded as a liability as of September 30, 2026.

 

Accounting Services – The Company engages an accounting firm to provide accounting and bookkeeping services, which is majority owned by the Company’s Chief Financial Officer (“CFO”), who serves as an independent contractor to the Company.

 

For the three and nine months ended September 30, 2026, the Company incurred expenses of $0.02 million and $0.06 million, respectively, related to services provided by the CFO’s accounting firm. For the three and nine months ended September 30, 2025, the Company incurred expenses of $0.01 million and $0.02 million, respectively, related to services provided by the CFO’s accounting firm. Such amounts are included in general and administrative expenses in the accompanying condensed consolidated statements of operations.

 

As of September 30, 2026 and December 31, 2025, there were no amounts payable to the accounting firm.

 

Software Development Services – The Company engages a software development company to provide software development services, which is wholly owned by the Company’s Chief Technology Officer (“CTO”), who is an employee of the Company.

 

For the three and nine months ended September 30, 2026, the Company incurred expenses of $0.1 million and $0.2 million, respectively, for software development services provided by the CTO’s company. For the three and nine months ended September 30, 2025, the Company incurred expenses of $0.03 million and $0.2 million, respectively, for software development services provided by the CTO’s company. Such amounts are included in research and development expense in the accompanying condensed consolidated statements of operations.

 

As of September 30, 2026 and December 31, 2025, amounts payable to the CTO’s software development company were $0.1 million and $0.05 million, respectively, and are included in accounts payable and accrued expenses in the accompanying condensed consolidated balance sheets.

 

The Company believes that the terms of its arrangements with these vendors are consistent with those that would have been obtained from unaffiliated third parties.

 

14. Commitments and Contingencies

 

Lease Agreement

 

The Company has a month-to-month lease for a suite at a cost of $530 per month. The Company incurred $2 thousand and $6 thousand of rent expense, including common tenant costs, during each of the three and nine months ended September 30, 2026 and 2025.

 

17

 

 

Litigation

 

From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recognized, if and when it is probable that a liability has been incurred and the amount can be reasonably estimated.

 

On November 6, 2025, ARC Group Limited and ARC Opportunity Fund Limited (together, “ARC”) filed a complaint against the Company and certain officers of the Company in the District Court of Minnesota, Fourth Judicial District (the “ARC complaint”). The ARC complaint alleges that the Company has breached certain contracts that the Company entered into with ARC before the closing of the Business Combination, including certain financial advisory contracts entered into by the Company at the direction of the sponsor of the Business Combination (the “sponsor”; the Company notes that the sponsor is an affiliate of ARC). Specifically, the ARC complaint asserts that the Company breached these contracts by issuing certain shares of Common Stock to ARC contemporaneously with the closing of the Business Combination and improperly cancelling those shares after the Business Combination as well as by failing to pay ARC certain cash amounts when due. The ARC complaint seeks an order of specific performance requiring the Company to reinstate the cancelled shares of Common Stock or, in the alternative, compensatory damages for such cancellation as well as payment of the other purported amounts due. The ARC complaint also asserts tort claims arising out of the Company’s actions and seeks compensatory damages (plus prejudgment interest) and punitive damages in connection with such claims but does not specify an amount of damages.

 

The Company notes that no shares of Common Stock were actually issued to ARC prior to or contemporaneously with the closing of the Business Combination and that, as of September 30, 2026 and as previously disclosed on the Form 10-K for the fiscal year ended December 31, 2025, the Company has recorded a forward contract to issue 124,065 shares of its Common Stock to ARC for success fees earned in connection with the Business Combination. As of September 30, 2026 and December 31, 2025, the Company has recorded aggregate cash liabilities payable to ARC equal to $0.4 million. The Company believes that the claim as asserted is overstated, and denies liability with respect to all disputed amounts and intends to defend itself vigorously. The Company is also assessing whether there are any counterclaims available to it arising out of self-dealing transactions between ARC and the sponsor. Accordingly, the Company has not recorded any additional liability arising out of the ARC complaint as the Company does not believe any incremental loss is probable, and the Company cannot estimate any reasonably possible loss or range of possible loss. On March 19, 2026, ARC voluntarily dismissed the complaint without prejudice.

 

The Company was not subject to any other material legal proceedings during the nine months ended September 30, 2026.

 

15. Subsequent Events

 

The Company has evaluated subsequent events occurring through November 16, 2026, the date the condensed consolidated financial statements were issued, for events requiring recording or disclosure in the Company’s condensed consolidated financial statements.

 

In October 2026, the Company entered into subscription agreements with two related party investors pursuant to which the Company agreed to issue and sell an aggregate of 174,884 shares of its Common Stock at prices between $5.54 and $5.78 per share. The Company received gross proceeds of approximately $1.0 million from the related party subscription agreements.

 

18

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion and analysis are intended to help you understand our business, financial condition, results of operations, liquidity, and capital resources. You should read this discussion in conjunction with the Company’s consolidated financial statements and related notes included elsewhere in this Report and in the Form 10-K.

 

In addition to historical financial analysis, this discussion and analysis contains forward-looking statements based upon current expectations that involve risks, uncertainties, and assumptions, as described under the heading “Cautionary Note Regarding Forward-Looking Statements.” Actual results and timing of selected events may differ materially from those anticipated in these forward-looking statements as a result of various factors, risks and uncertainties, including those set forth under “Risk Factors” included elsewhere (or incorporated by reference) in this Report and in the Form 10-K. Unless the context otherwise requires, references in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” to “OneMedNet”, “we”, “us”, “our,” and “the Company” are intended to mean the business and operations of OneMedNet Corporation and its consolidated subsidiary following the completion of the business combination on November 7, 2023 involving OneMedNet Solutions Corporation (formerly named OneMedNet Corporation) (“Legacy ONMD”), with Legacy ONMD surviving as a wholly owned subsidiary of Data Knights Acquisition Corp. (“Data Knights”) (the “Business Combination”).

 

Company Overview

 

We are a healthcare technology company focused on the acquisition, curation, de-identification and commercialization of real-world clinical data. Through our proprietary iRWD™ platform and network of healthcare providers, we provide pharmaceutical companies, medical device manufacturers, contract research organizations, academic institutions and artificial intelligence developers with access to longitudinal, multimodal clinical datasets for use in research, product development, regulatory submissions and real-world evidence generation.

 

Our platform identifies, de-identifies and curates clinical data obtained from healthcare providers, including electronic health records, clinical notes, medical imaging, laboratory results and other clinical information. We combine our technology, healthcare provider network and clinical expertise to develop fit-for-purpose datasets based on customer-specific requirements.

 

Reverse Stock Split

 

At the Company’s 2026 annual meeting of stockholders held on September 18, 2026, the Company’s stockholders approved a proposal to effect a reverse stock split of the Company’s common stock by a ratio ranging from any whole number between 1-for-5 and 1-for-20, as determined by the Board of Directors in its discretion.

 

On September 29, 2026, the Company effected a 1-for-10 reverse stock split of the Company’s common stock, par value $0.0001 per share (“Common Stock”) (the “Reverse Stock Split”). As a result of the Reverse Stock Split, every 10 shares of the Company’s Common Stock issued and outstanding were automatically converted into one new share of Common Stock. Proportionate adjustments were also made to the number of shares available under the Company’s equity incentive plans and the exercise price and number of shares underlying outstanding restricted stock units, warrants, and other equity awards. The Reverse Stock Split did not decrease the number of authorized shares of Common Stock and preferred stock or otherwise affect the par value of the Common Stock. No fractional shares were issued in connection with the Reverse Stock Split and any fractional shares resulting from the Reverse Stock Split were rounded up to the nearest whole share for stockholders of record who would be entitled to receive fractional shares pursuant to the Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of the Company effecting the Reverse Stock Split.

 

All information presented herein, unless otherwise indicated herein, reflects the Reverse Stock Split of the Company’s outstanding shares of common stock, and unless otherwise indicated, all such amounts and corresponding conversion price or exercise price data set forth herein have been adjusted to give effect to such Reverse Stock Split.

 

Nasdaq Compliance

 

On April 14, 2026, the Company received notice from The Nasdaq Stock Market (“Nasdaq”) indicating that the Company, based on the closing bid price of the shares of Common Stock for the last 30 consecutive business days, is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until October 12, 2026, to regain compliance with the Bid Price Rule. To regain compliance, the minimum bid price of the shares of Common Stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-calendar day grace period.

 

On October 13, 2026, we received a letter from Nasdaq notifying us that we had regained compliance with the Bid Price Rule and accordingly, the matter is now closed.

 

Key Components of Consolidated Statements of Operations

 

Revenue

 

The Company generates revenue from its iRWD platform, which provides regulatory grade imaging and clinical data in the pharmaceutical, device manufacturing, contract research organizations, and AI markets. iRWD is sold on a fixed fee basis based on the number of data units and the cost per data unit committed to in the customer contract. Revenue is recognized when the data is delivered and accepted by the customer. The Company’s legacy BEAM platform was decommissioned in May 2025, and no revenue was generated from this platform thereafter.

 

19

 

 

The Company excludes from revenue taxes collected from a customer that are assessed by a governmental authority and imposed on and concurrent with a specific revenue-producing transaction. The transaction price for the products is the invoiced amount. Advance billings from contracts are deferred and recognized as revenue when earned. Deferred revenue consists of payments received in advance of performance under the contract. Such amounts are generally recognized as revenue over the contractual period. The Company receives payments from customers based upon contractual billing schedules. Accounts receivable are recorded when the right to consideration becomes unconditional. Payment terms on invoiced amounts typically range from zero to 90 days, with typical terms of 30 days.

 

Cost of Revenue

 

Our cost of revenue consists primarily of (i) software and hosting costs associated with operating our real-world data platform, (ii) data costs, which include amounts paid to data partners to acquire the clinical and imaging data we deliver to customers, and (iii) personnel costs for employees directly involved in curating and delivering data.

 

General and Administrative

 

General and administrative functions include finance, legal, operations, human resources, and information technology support. These functions include costs for items such as salaries and benefits and other personnel-related costs, maintenance and supplies, professional fees for external legal, accounting, and other consulting services, and depreciation expense.

 

Research and Development

 

Costs incurred in the research and development of our products are expensed as incurred. Research and development costs include personnel, contracted services, materials, and indirect costs involved in the design and development of new products and services, as well as hosting expense.

 

Sales and Marketing

 

Our sales and marketing costs consist of labor and tradeshow costs.

 

Other (Income) Expenses, Net

 

Interest Expense

 

Interest expense consists of interest incurred on our outstanding debt facilities, including loans with related parties, deferred underwriter fees and insurance premiums paid in exchange for a note payable.

 

Change in Fair Value of Warrants

 

We have outstanding warrants that were issued at the closing of the Business Combination, which are accounted for as liabilities at fair value. These warrants are subsequently re-measured at fair value on our consolidated balance sheets at the end of each reporting period and at settlement, as applicable, and changes in fair value are recognized in the consolidated statements of operations.

 

Change in Fair Value of Convertible Notes

 

We have elected the fair value option of accounting for the PIPE Notes (as defined in the Form 10-K) issued in the Business Combination and the Yorkville Note (as defined in the Form 10-K) issued with the 2024 SEPA. These instruments contained embedded derivatives that would require bifurcation and separate accounting; therefore, we made the election to measure the entire contingently convertible debt instruments, including accrued interest, at fair value. These instruments are subsequently re-measured at fair value on our consolidated balance sheets at the end of each reporting period and at settlement, as applicable, and changes in fair value are recognized in the consolidated statements of operations. The PIPE Notes and Yorkville Note were both settled in 2025 and were no longer outstanding as of December 31, 2025.

 

20

 

 

Change in Fair Value of Crypto Assets – Bitcoin

 

We previously adopted a Bitcoin strategy on the balance sheets as a forward-looking approach to corporate treasury management that incorporates digital currencies. Our Bitcoin holdings were held at fair value on the consolidated balance sheets and are re-measured at the end of each reporting period based on the quoted end-of-day price provided by a reputable and liquid exchange. As of September 30, 2026, we no longer hold Bitcoin or any other crypto assets.

 

Realized Loss (Gain) on Sale of Crypto Assets – Bitcoin

 

As part of our Bitcoin strategy, we routinely sell quantities held as part of our corporate treasury strategy to fund operations as needed. We recognize a realized gain upon sale when the price of Bitcoin is higher than its initial purchase price.

 

Change in Fair Value of SEPA Derivative Liabilities

 

We entered into the 2024 SEPA and 2026 SEPA, which provide us with the right, but not the obligation, to require Yorkville to purchase shares of our Common Stock during the respective commitment periods, subject to certain limitations. We recognize a put option liability upon execution of each SEPA and a forward option liability upon delivery of a notice to sell shares of our Common Stock. These derivative liabilities are subsequently remeasured at fair value at each reporting date, with changes in fair value recognized in our consolidated statements of operations.

 

Results of Operations

 

Comparison of the Three Months Ended September 30, 2026 and 2025

 

The following table sets forth our condensed consolidated statements of operations data for the periods presented (in thousands):

 

   Three Months Ended September 30,   Change 
   2026   2025   $   % 
Revenue                    
Data delivery revenue   1,023    177    846    478%
Total revenue   1,023    177    846    478%
Cost of revenue   1,386    399    987    247%
Gross margin   (363)   (222)   (141)   64%
Operating expenses                    
General and administrative   1,185    1,386    (201)   -15%
Sales and marketing   262    304    (42)   -14%
Research and development   424    323    101    31%
Total operating expenses   1,871    2,013    (142)   -7%
Loss from operations   (2,234)   (2,235)   1    -0%
Other (income) expense, net                    
Interest expense   8    6    2    33%
Change in fair value of warrants   (19)   20    (39)   -195%
Change in fair value of crypto assets – Bitcoin   -    (55)   55    -100%
Realized gain on sale of crypto assets – Bitcoin   -    (54)   54    -100%
Change in fair value of 2024 SEPA derivative liabilities   -    402    (402)   -100%
Change in fair value of 2026 SEPA derivative liabilities   436    -    436    100%
Gain on troubled debt restructurings   -    (1,862)   1,862    -100%
Loss on extinguishment of debt   -    41    (41)   -100%
Other expense, net   1    8    (7)   -88%
Total other expense (income), net   426    (1,494)   1,920    -129%
Net (loss) income  $(2,660)  $(741)  $(1,919)   -259%

 

21

 

 

Revenue

 

Total revenue increased by $0.8 million, or 478%, during the three months ended September 30, 2026, compared to the three months ended September 30, 2025. The increase was attributable to a $0.8 million increase in data delivery revenue as the Company continued its transition to a unified RWD platform, driving increased customer adoption and higher data delivery volumes.

 

Cost of Revenue

 

Cost of revenue was $1.4 million for the three months ended September 30, 2026, compared to $0.4 million for the three months ended September 30, 2025, an increase of $1.0 million, or 247%. The increase was primarily driven by a $0.5 million increase in software and hosting costs associated with operating and scaling the Company’s AI-enabled real-world data platform, a $0.4 million increase in iRWD costs to support higher data delivery revenue through the iRWD platform, and a $0.1 million increase in personnel costs due to headcount growth.

 

General and Administrative

 

General and administrative expenses were $1.2 million for the three months ended September 30, 2026, compared to $1.4 million for the three months ended September 30, 2025, a decrease of $0.2 million, or 15%. The decrease was primarily attributable to a $0.4 million decrease in professional fees, largely due to lower consulting and legal costs, which is partially offset by a $0.2 million increase in share-based compensation expense related to equity awards granted during the second half of 2025 and 2026,

 

Sales and Marketing

 

Sales and marketing expenses for the three months ended September 30, 2026, were generally consistent with sales and marketing expenses for the three months ended September 30, 2025.

 

Research and Development

 

Research and development expenses were $0.4 million for the three months ended September 30, 2026, compared to $0.3 million for the three months ended September 30, 2025, an increase of $0.1 million, or 31%. The increase was primarily attributable to a $0.1 million increase in share-based compensation expense related to equity awards granted during the second half of 2025 and 2026.

 

Interest Expense

 

Interest expense for the three months ended September 30, 2026 was generally consistent with interest expense for the three months ended September 30, 2025.

 

22

 

 

Change in Fair Value of Warrants

 

The change in fair value of warrants is composed of the re-measurement adjustment for our liability-classified warrants that were issued in connection with the Business Combination. The change is mainly due to the resulting fluctuations in the market price of shares of Common Stock.

 

Change in Fair Value of Crypto Assets – Bitcoin

 

The change in fair value of crypto assets – Bitcoin during the three months ended September 30, 2025, reflected fluctuations in the price of Bitcoin. There was no corresponding change in fair value during the three months ended September 30, 2026, as we liquidated all of our Bitcoin holdings during the second quarter of 2026.

 

Realized Gain on Sale of Crypto Assets – Bitcoin

 

The realized gain on sale of crypto assets – Bitcoin during the three months ended September 30, 2025, reflected the difference between the carrying value of Bitcoin and its market price upon sale. There was no corresponding realized gain during the three months ended September 30, 2026, as we liquidated all of our Bitcoin holdings during the second quarter of 2026.

 

Change in Fair Value of SEPA Derivative Liabilities

 

The change in fair value of SEPA derivative liabilities is primarily driven by assumptions regarding the expected timing and volume of Common Stock sales to Yorkville and the Company’s projected stock price over the applicable commitment period. The change in fair value during the three months ended September 30, 2026, related to the 2026 SEPA, while the change in fair value during the three months ended September 30, 2025, related to the 2024 SEPA.

 

Gain on Troubled Debt Restructurings

 

Gain on troubled debt restructurings during the three months ended September 30, 2025 was primarily driven by restructured trade payables with two separate vendors which resulted in a gain of $1.9 million. During the three months ended September 30, 2026, we did not restructure any of our debt or trade payables.

 

Comparison of the Nine Months Ended September 30, 2026 and 2025

 

The following table sets forth our condensed consolidated statements of operations data for the periods presented (in thousands):

 

   Nine Months Ended September 30,   Change 
   2026   2025   $   % 
Revenue                    
Subscription revenue  $-   $105   $(105)   -100%
Data delivery revenue   1,410    363    1,047    288%
Total revenue   1,410    468    942    201%
Cost of revenue   2,928    1,136    1,792    158%
Gross margin   (1,518)   (668)   (850)   127%
Operating expenses                    
General and administrative   3,439    3,999    (560)   -14%
Sales and marketing   1,031    846    185    22%
Research and development   1,059    1,072    (13)   -1%
Total operating expenses   5,529    5,917    (388)   -7%
Loss from operations   (7,047)   (6,585)   (462)   7%
Other (income) expense, net                    
Interest expense   27    59    (32)   -54%
Change in fair value of warrants   (66)   23    (89)   -387%
Change in fair value of convertible notes   -    (1,285)   1,285    -100%
Change in fair value of crypto assets – Bitcoin   (147)   782    (929)   -119%
Realized loss (gain) on sale of crypto assets – Bitcoin   234    (899)   1,133    -126%
Change in fair value of 2024 SEPA derivative liabilities   (245)   (32)   (213)   666%
Change in fair value of 2026 SEPA derivative liabilities   436    -    436    100%
Gain on troubled debt restructurings   -    (5,569)   5,569    -100%
Loss on extinguishment of debt   -    41    (41)   -100%
Other (income) expense, net   (1)   (44)   43    -98%
Total other (income) expense, net   238    (6,924)   7,162    -103%
Net (loss) income  $(7,285)  $339   $(7,624)   -2249%

 

23

 

 

Revenue

 

Total revenue increased by $0.9 million, or 201%, during the nine months ended September 30, 2026, compared to the nine months ended September 30, 2025. The increase was primarily attributable to a $1.0 million increase in data delivery revenue as the Company continued its transition to a unified RWD platform, driving increased customer adoption and higher data delivery volumes. This growth was partially offset by a $0.1 million decrease in subscription revenue due to the decommissioning of the BEAM platform in May 2025.

 

Cost of Revenue

 

Cost of revenue was $2.9 million for the nine months ended September 30, 2026, compared to $1.1 million for the nine months ended September 30, 2025, an increase of $1.8 million, or 158%. The increase was primarily driven by a $1.1 million increase in software and hosting costs associated with operating and scaling the Company’s AI-enabled real-world data platform, a $0.5 million increase in iRWD costs to support higher data delivery revenue through the iRWD platform, and a $0.2 million increase in personnel costs due to headcount growth.

 

General and Administrative

 

General and administrative expenses were $3.4 million for the nine months ended September 30, 2026, compared to $4.0 million for the nine months ended September 30, 2025, representing a decrease of $0.6 million, or 14%. The decrease was primarily attributable to a $1.0 million reduction in professional fees, primarily due to lower legal, consulting, and other professional service costs, and a $0.1 million decrease in other general and administrative expenses. These decreases were partially offset by a $0.5 million increase in share-based compensation expense related to equity awards granted during 2025 and 2026 and a $0.1 million increase in salaries and related personnel costs resulting from headcount growth.

 

Sales and Marketing

 

Sales and marketing expenses were $1.0 million for the nine months ended September 30, 2026, compared to $0.8 million for the nine months ended September 30, 2025, representing an increase of $0.2 million, or 22%. The increase was primarily attributable to a $0.1 million increase in personnel costs due to headcount growth and a $0.1 million increase in consulting costs resulting from business development initiatives intended to support growth of the Company’s iRWD platform.

 

Research and Development

 

Research and development expenses for the nine months ended September 30, 2026, were generally consistent with research and development expenses for the nine months ended September 30, 2025.

 

24

 

 

Interest Expense

 

Interest expense for the nine months ended September 30, 2026 was generally consistent with interest expense for the nine months ended September 30, 2025.

 

Change in Fair Value of Warrants

 

The change in fair value of warrants is composed of the re-measurement adjustment for our liability-classified warrants that were issued in connection with the Business Combination. The change is mainly due to the resulting fluctuations in the market price of shares of Common Stock.

 

Change in Fair Value of Convertible Notes

 

The change in fair value of convertible notes is composed of the re-measurement adjustment for the PIPE Notes and Yorkville Note which are carried at fair value. The change is mainly due to the resulting fluctuations in the market price of shares of Common Stock. Both instruments were converted or repaid in the second quarter of 2025; therefore, no re-measurement adjustment was required for the nine months ended September 30, 2026.

 

Change in Fair Value of Crypto Assets – Bitcoin

 

The change in fair value of crypto assets – Bitcoin during the nine months ended September 30, 2026 and 2025 reflected fluctuations in the price of Bitcoin.

 

Realized Loss (Gain) on Sale of Crypto Assets – Bitcoin

 

The realized loss (gain) on sale of crypto assets – Bitcoin during the nine months ended September 30, 2026 and 2025 reflected the difference between the carrying value of Bitcoin and its market price upon sale.

 

Change in Fair Value of SEPA Derivative Liabilities

 

The change in fair value of SEPA derivative liabilities is primarily driven by assumptions regarding the expected timing and volume of Common Stock sales to Yorkville and the Company’s projected stock price over the applicable commitment period. For the nine months ended September 30, 2026, the change in fair value included amounts related to both the 2024 SEPA and the 2026 SEPA, whereas the change in fair value for the nine months ended September 30, 2025, related solely to the 2024 SEPA.

 

Gain on Troubled Debt Restructurings

 

Gain on troubled debt restructurings during the nine months ended September 30, 2025 was primarily driven by our settlement of deferred underwriter fees which resulted in a gain of $2.8 million. In addition, we restructured trade payables with five separate vendors leading to an additional gain of $2.8 million. During the nine months ended September 30, 2026, we did not restructure any of our debt or trade payables.

 

Liquidity and Capital Resources

 

As of September 30, 2026, our principal sources of liquidity were proceeds from related party investors and the 2024 SEPA.

 

The following table shows net cash and cash equivalents used in operating activities, net cash and cash equivalents used in investing activities, and net cash and cash equivalents provided by financing activities during the periods presented:

 

   Nine Months Ended September 30, 
   2026   2025 
Net cash provided by (used in)          
Operating activities  $(4,839)  $(5,455)
Investing activities   407    2,358 
Financing activities   3,984    3,074 

 

25

 

 

Operating Activities

 

Our net cash and cash equivalents used in operating activities consists of net loss adjusted for certain non-cash items, including depreciation and amortization, stock-based compensation expense, changes in fair value of liability classified financial instruments, as well as changes in operating assets and liabilities. The primary changes in working capital items, such as the changes in accounts receivable and deferred revenue, result from the difference in timing of payments from our customers related to contract performance obligation. This may result in an operating cash flow source or use for the period, depending on the timing of payments received as compared to the fulfillment of the performance obligation.

 

During the nine months ended September 30, 2026, we used $4.8 million of cash in operating activities, primarily resulting from our net loss of $7.3 million, offset by non-cash charges of $1.6 million and cash provided by changes in our operating assets and liabilities of $0.9 million.

 

During the nine months ended September 30, 2025, we used $5.5 million of cash in operating activities, primarily resulting from non-cash charges of $6.3 million, offset by our net income of $0.3 million and cash provided by changes in our operating assets and liabilities of $0.5 million.

 

Investing Activities

 

Our investing activities have consisted primarily of property and equipment purchases and Bitcoin purchases and sales.

 

During the nine months ended September 30, 2026, net cash provided by investing activities was $0.4 million, primarily consisting of proceeds from Bitcoin sales of $0.4 million.

 

During the nine months ended September 30, 2025, net cash provided by investing activities was $2.4 million, primarily consisting of proceeds from Bitcoin sales of $4.8 million offset by Bitcoin purchases of $2.4 million.

 

Financing Activities

 

During the nine months ended September 30, 2026, net cash provided by financing activities was $4.0 million, consisting of $3.4 million in net proceeds from related party investments and $1.0 million in net proceeds from the 2024 SEPA, partially offset by debt repayments of $0.4 million.

 

During the nine months ended September 30, 2025, net cash provided by financing activities was $3.1 million, consisting of $1.7 million in net proceeds from related party investments and $2.5 million in net proceeds from private placements, partially offset by aggregate repayments of $1.1 million of debt and deferred underwriter fees.

 

Contractual Obligations and Commitments and Going Concern Outlook

 

Currently, management does not believe that our cash and cash equivalents are sufficient to meet our foreseeable cash needs for at least the next 12 months. Our foreseeable cash needs, in addition to our recurring operating expenses, include our expected capital expenditures to support the expansion of our infrastructure and workforce, interest expense and minimum contractual obligations. Management intends to raise cash for operations through debt and equity offerings. As a result of the Company’s recurring loss from operations and the need for additional financing to fund its operating and capital requirements there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company’s ability to continue as a going concern.

 

Our future capital requirements will depend on many factors, including our growth rate, the timing and extent of spending to support research and development efforts, the expansion of sales and marketing activities, the introduction of new and enhanced product and service offerings, and the cost of any future acquisitions of technology or businesses. In the event that additional financing is required from outside sources, we may be unable to raise the funds on acceptable terms, if at all.

 

26

 

 

The following table summarizes our material cash requirements as of September 30, 2026:

 

       Payments due in: 
   Total   Less than 1 year   1-3 years 
Accounts payable & accrued expenses  $4,504   $4,504   $- 
Loans payable   563    464    99 
   $5,067   $4,968   $99 

 

Critical Accounting Policies and Estimates

 

Our management’s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements which have been prepared in accordance with GAAP. In preparing our financial statements, we make estimates, assumptions, and judgments that can have a significant impact on our reported revenue, results of operations, and net income or loss, as well as on the value of certain assets and liabilities on our balance sheet during and as of the reporting periods. These estimates, assumptions, and judgments are necessary because future events and their effects on our results of operations and the value of our assets cannot be determined with certainty and are made based on our historical experience and on other assumptions that we believe to be reasonable under the circumstances. These estimates may change as new events occur or additional information is obtained, and we may periodically be faced with uncertainties, the outcomes of which are not within our control and may not be known for a prolonged period of time. Because the use of estimates is inherent in the financial reporting process, actual results could differ from those estimates.

 

For a discussion of our critical accounting estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Form 10-K, the notes to our audited financial statements appearing in the Form 10-K, and the notes to the financial statements appearing elsewhere in this Report. Except as described in this Report, there have been no material changes to these critical accounting policies and estimates through September 30, 2026 from those discussed in the Form 10-K.

 

Recently Issued and Adopted Accounting Pronouncements

 

A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our condensed consolidated financial statements included elsewhere in this Report.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act), as of September 30, 2026. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2026, our disclosure controls and procedures were ineffective due to material weaknesses in our internal controls over financial reporting related to user access and segregation of duties, the lack of a formalized control environment and oversight of controls over financial reporting, and revenue recognition.

 

27

 

 

Material Weaknesses

 

Management is aware of material weaknesses in the Company’s internal control related to user access/segregation of duties, lack of a formalized control environment and oversight of controls over financial reporting and revenue recognition. Due to the limited transactional volume currently experienced, combined with our financial limitations, we do not currently have an expanded accounting department that would allow us to better segregate duties. Over time, as we continue to grow and add accounting staff, we expect to continue to enhance our internal control structure, including appropriate segregation of duties. Management has begun taking remediation steps to address the material weaknesses, including the hiring of a full-time controller in July 2025 and adding additional review procedures over our financial records. This remediation is an ongoing process and there can be no assurance that it will effectively address the material weaknesses.

 

Changes in Internal Control Over Financial Reporting

 

Except as described above, there were no other changes in our internal control over financial reporting during the three months ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

For information regarding litigation, see Part I – Item 1. Condensed Consolidated Financial Statements, Note 14 - Commitments and Contingencies.

 

Item 1A. Risk Factors.

 

In addition to the other information set forth in this Report, you should carefully consider the factors discussed in the “Risk Factors” in the Form 10-K and our other public filings, which could materially affect our business, financial condition or future results. There have been no material changes from risk factors previously disclosed in “Risk Factors” in the Form 10-K and our other public filings.

 

28

 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 

 

The Company entered into a subscription agreement, dated July 30, 2026, with Dr. Thomas Kosasa, a director and related party of the Company, pursuant to which the Company issued 144,928 shares of Common Stock to Dr. Kosasa at a price of $6.90 per share. The Company received net proceeds of approximately $1,000,000 from the related party subscription agreement. These shares were issued in reliance on the exemption from registration provided by Section 4(a)(2) under the Securities Act.

 

The Company entered into a subscription agreement, dated September 10, 2026, with Dr. Jeffrey Yu, a director, officer and related party of the Company, pursuant to which the Company issued 14,286 shares of Common Stock to Dr. Yu at a price of $6.30 per share. The Company received net proceeds of approximately $90,000 from the related party subscription agreement. These shares were issued in reliance on the exemption from registration provided by Section 4(a)(2) under the Securities Act.

 

Except as set forth above, during the three months ended September 30, 2026, we did not have issuances of unregistered securities not previously included in a Current Report on Form 8-K.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

During the three months ended September 30, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

 

Item 6. Exhibits.

 

The following documents are included as exhibits to this Report:

 

Exhibit Number   Description
3.1   Third Amended and Restated Certificate of Incorporation of OneMedNet Corporation (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K, filed with the SEC on November 13, 2023).
3.2   Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of OneMedNet Corporation (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K, filed with the SEC on September 29, 2026).
3.3   Amended and Restated Bylaws of OneMedNet Corporation (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on November 13, 2023).
10.1   Standby Equity Purchase Agreement, dated as of July 1, 2026, by and between OneMedNet Corporation and YA II PN, Ltd. (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on July 1, 2026).
10.2*   OneMedNet Corporation Amended and Restated 2022 Equity Incentive Plan.
31.1*   Certification of Chief Executive Officer (Principal Executive Officer) Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*   Certification of Chief Financial Officer (Principal Financial Officer) Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1#   Certification of Chief Executive Officer (Principal Executive Officer) Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2#   Certification of Chief Financial Officer (Principal Financial Officer) Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

 

* Filed herewith.

 

# The certifications furnished in Exhibit 32.1 and Exhibit 32.2 hereto are deemed to accompany this Report and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.

 

29

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on November 16, 2026.

 

  OneMedNet Corporation
     
  By: /s/ Robert Golden
    Robert Golden
    Chief Financial Officer
    (Duly Authorized Officer and Principal Financial and Accounting Officer)

 

30

 

 

Exhibit 10.2

 

ONEMEDNET CORPORATION

AMENDED AND RESTATED 2022 EQUITY INCENTIVE PLAN

 

(amended and restated effective September 18, 2026)

 

1. Purpose. The purpose of the OneMedNet Corporation Amended and Restated 2022 Equity Incentive Plan (the “Plan”) is to provide a means through which the Company and its Affiliates may attract and retain key personnel and to provide a means whereby Directors, officers, Employees, and Consultants (and prospective Directors, officers, Employees, and Consultants) of the Company and its Affiliates can acquire and maintain an equity interest in the Company, or be paid incentive compensation, which may (but need not) be measured by reference to the value of Common Shares, thereby strengthening their commitment to the welfare of the Company and its Affiliates and aligning their interests with those of the Company’s stockholders.

 

2. Definitions. The following definitions shall be applicable throughout the Plan:

 

(a) “Affiliate” means (i) any person or entity that directly or indirectly controls, is controlled by or is under common control with the Company and/or (ii) to the extent provided by the Committee, any person or entity in which the Company has a significant interest. The term “control” (including, with correlative meaning, the terms “controlled by” and “under common control with”), as applied to any person or entity, means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such person or entity, whether through the ownership of voting or other securities, by contract or otherwise.

 

(b) “Award” means, individually or collectively, any Incentive Stock Option, Nonqualified Stock Option, Stock Appreciation Right, Restricted Stock, Restricted Stock Unit, Stock Bonus Award, and Performance Compensation Award granted under the Plan.

 

(c) “Award Agreement” means a written or electronic agreement between the Company and a Participant setting forth the terms, conditions and restrictions of the Award granted to the Participant

 

(d) “Board” means the Board of Directors of the Company.

 

(e) “Business Combination” has the meaning given such term in the definition of “Change in Control.”

 

(f) “Cause” means, in the case of a particular Award, unless the applicable Award Agreement or the Participant’s employment agreement with the Company states otherwise, the Company’s termination of the Participant’s employment with the Company as a result of: (i) fraud, embezzlement or other willful act of material dishonesty by the Participant in connection with or relating to the Participant’s employment with the Company; (ii) theft or misappropriation of property, information or other assets by the Participant in connection with the Participant’s employment with the Company which results in or could reasonably be expected to result in material loss, damage or injury to the Company, its goodwill, business or reputation; (iii) the Participant’s commission, guilty plea, no contest plea or similar plea for any felony or crime involving moral turpitude; (iv) the Participant’s use of alcohol or drugs while working that materially interferes with the Participant’s duties; (v) material breach of a material Company policy, or material breach of a Company policy that results in or could reasonably be expected to result in material loss, damage or injury to the Company, its goodwill, business or reputation; (vi) the Participant’s material breach of any of Participant’s obligations under this Agreement; or (vii) the Participant’s repeated insubordination, or refusal (other than as a result of a Disability or physical or mental illness) to carry out or follow specific reasonable and lawful instructions, duties or assignments given by the Board which are consistent with the Participant’s position with the Company. Additionally, in the event that the basis for Cause is, in the reasonable good faith determination of the Company not reasonably subject to cure, then such thirty (30) days’ prior notice of termination for Cause shall not be required, and such termination shall be effective on the date the Company delivers notice of such termination for Cause.

 

A-1

 

 

(g) “Change in Control” shall, in the case of a particular Award, unless the applicable Award Agreement states otherwise or contains a different definition of “Change in Control,” be deemed to occur upon:

 

(i) Any sale, lease, exchange or other transfer (in one or a series of related transactions) of all or substantially all of the assets of the Company;

 

(ii) Any “Person” as such term is used in Section 13(d) and Section 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) becomes, directly or indirectly, the “beneficial owner” as defined in Rule 13d-3 under the Exchange Act of securities of the Company that represent more than 50% of the combined voting power of the Company’s then outstanding voting securities (the “Outstanding Company Voting Securities”); provided, however, that for purposes of this Section 2(g)(ii), the following acquisitions shall not constitute a Change in Control: (I) any acquisition directly from the Company principally for bona fide equity financing purposes, (II) any acquisition by the Company, (III) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any Affiliate, (IV) any acquisition by any corporation pursuant to a transaction that complies with Sections 2(g)(iv)(A) and 2(g)(iv)(B), and (V) any acquisition involving beneficial ownership of less than 50% of the then-outstanding Common Shares (the “Outstanding Company Common Shares”) or the Outstanding Company Voting Securities that is determined by the Board, based on review of public disclosure by the acquiring Person with respect to its passive investment intent, not to have a purpose or effect of changing or influencing the control of the Company; provided, however, that for purposes of this clause (V), any such acquisition in connection with (x) an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents or (y) any “Business Combination” (as defined below) shall be presumed to be for the purpose or with the effect of changing or influencing the control of the Company;

 

(iii) During any period of not more than two (2) consecutive years, individuals who constitute the Board as of the beginning of the period (the “Incumbent Directors”) cease for any reason to constitute at least a majority of the Board, provided that any person becoming a director subsequent to the beginning of such period, whose election or nomination for election was approved by a vote of at least two-thirds of the Incumbent Directors then on the Board (either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee for director, without written objection to such nomination) will be an Incumbent Director; provided, however, that no individual initially elected or nominated as a director of the Company as a result of an actual or threatened election contest with respect to directors or as a result of any other actual or threatened solicitation of proxies by or on behalf of any person other than the Board will be deemed to be an Incumbent Director;

 

A-2

 

 

(iv) Consummation of a merger, amalgamation or consolidation (a “Business Combination”) of the Company with any other corporation, unless, following such Business Combination, (A) all or substantially all of the individuals and entities that were the beneficial owners of the Outstanding Company Common Shares and the Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the then-outstanding shares of common stock (or, for a non-corporate entity, equivalent securities) and the combined voting power of the then-outstanding voting securities entitled to vote generally in the election of directors (or, for a non-corporate entity, equivalent governing body), as the case may be, of the entity resulting from such Business Combination (including, without limitation, an entity that, as a result of such transaction, owns the Company or all or substantially all of the Company’s assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership immediately prior to such Business Combination of the Outstanding Company Common Shares and the Outstanding Company Voting Securities, as the case may be, and (B) at least a majority of the members of the board of directors (or, for a non-corporate entity, equivalent governing body) of the entity resulting from such Business Combination were Incumbent Directors at the time of the execution of the initial agreement or of the action of the Board providing for such Business Combination;

 

(v) Stockholder approval of a plan of complete liquidation of the Company.

 

(vi) A transaction shall not constitute a Change in Control if its sole purpose is to change the state of the Company’s incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company’s securities immediately before such transactions. In addition, if any Person (as defined above) is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered to cause a Change in Control. If required for compliance with Code Section 409A, in no event will a Change in Control be deemed to have occurred if such transaction is not also a “change in the ownership or effective control of” the Company or “a change in the ownership of a substantial portion of the assets of” the Company as determined under Treasury Regulation Section 1.409A-3(i)(5) (without regard to any alternative definition thereunder).

 

(h) “Code” means the Internal Revenue Code of 1986, as amended, and any successor thereto. Reference in the Plan to any section of the Code shall be deemed to include any regulations or other interpretative guidance under such section, and any amendments or successor provisions to such section, regulations or guidance.

 

(i) “Committee” means a committee of at least two people as the Board may appoint to administer the Plan or, if no such committee has been appointed by the Board, the Board.

 

A-3

 

 

(j) “Common Shares” or “Common Stock” means shares of the Company’s common stock (and any stock or other securities into which such shares may be converted or into which they may be exchanged).

 

(k) “Company” means OneMedNet Corporation, a Delaware corporation.

 

(l) “Consultant” means any person, including an advisor, consultant or agent, engaged by the Company or a Parent or Subsidiary to render services to such entity or who renders, or has rendered, services to the Company, or any Parent, Subsidiary or affiliate and is compensated for such services.

 

(m) “Date of Grant” means the date on which the granting of an Award is authorized, or such other date as may be specified in such authorization.

 

(n) “Director” means a member of the Board.

 

(o) “Disability” means, for the purpose of Incentive Stock Options, total and permanent disability as defined in Code Section 22(e)(3); and for the purpose of Awards other than Incentive Stock Options, means the inability of the Participant to perform the Participant’s material duties hereunder with a reasonable accommodation due to a physical or mental injury, infirmity or incapacity for one hundred and twenty (120) days (including weekends and holidays) in any three hundred sixty-five (365) day period. The Participant shall reasonably cooperate with the Company if a question arises as to whether the Participant has become disabled (including, without limitation, submitting to reasonable examinations by one or more medical doctors and other health care specialists reasonably selected by the Company and authorizing such medical doctors and other health care specialists to discuss the Participant’s condition with the Company).

 

(p) “Effective Date” means the date means the date on which the Plan was originally approved by the stockholders of the Company.

 

(q) “Eligible Director” means a person who is a “non-employee director” within the meaning of Rule 16b-3 under the Exchange Act.

 

(r) “Eligible Person” with respect to an Award denominated in Common Shares, means any (i) Employee; provided, however, that no such employee covered by a collective bargaining agreement shall be an Eligible Person unless and to the extent that such eligibility is set forth in such collective bargaining agreement which includes rules regarding equity entitlement or in an agreement or instrument relating thereto; (ii) Director of the Company or an Affiliate; (iii) Consultant to the Company or an Affiliate; provided that if the Securities Act applies such persons must be eligible to be offered securities registrable on Form S-8 under the Securities Act; or (iv) prospective employees, directors, officers, consultants or advisors who have accepted offers of employment or consultancy from the Company or its Affiliates (and would satisfy the provisions of clauses (i) through (iii) above once he or she begins employment with or begins providing services to the Company or its Affiliates).

 

(s) “Employee” means any person, including officers and Directors, employed by the Company or any Affiliate or Subsidiary of the Company. Neither service as a Director nor payment of a director’s fee by the Company will be sufficient to constitute “employment” by the Company

 

A-4

 

 

(t) “Exchange Act” has the meaning given such term in the definition of “Change in Control,” and any reference in the Plan to any section of (or rule promulgated under) the Exchange Act shall be deemed to include any rules, regulations or other interpretative guidance under such section or rule, and any amendments or successor provisions to such section, rules, regulations or guidance.

 

(u) “Exchange Program” means a program under which outstanding Awards are amended to provide for a lower Exercise Price or surrendered or cancelled in exchange for (i) Awards with a lower Exercise Price, (ii) a different type of Award or awards under a different equity incentive plan, (iii) cash, or (iv) a combination of (i), (ii) and/or (iii). Notwithstanding the preceding, the term Exchange Program does not include (A) any action taken in connection with Section 13 or with a Change in Control transaction nor (B) any transfer or other disposition permitted under Section 15(b). For the purpose of clarity, each of the actions described in the prior sentence, none of which constitute an Exchange Program, may be undertaken (or authorized) by the Committee in its sole discretion without approval by the Company’s stockholders.

 

(v) “Exercise Price” has the meaning given such term in Section 7(b) of the Plan.

 

(w) “Fair Market Value” means, as of any date, the value of Common Shares determined as follows:

 

(i) If the Common Shares are listed on any established stock exchange or a national market system will be the closing sales price for such shares (or the closing bid, if no sales were reported) as quoted on such exchange or system on the day of determination, as reported in The Wall Street Journal or such other source as the Committee deems reliable;

 

(ii) If the Common Shares are regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market Value of a Common Share will be the mean between the high bid and low asked prices for the Common Shares on the day of determination, as reported in The Wall Street Journal or such other source as the Committee deems reliable; or

 

(iii) In the absence of an established market for the Common Shares, the Fair Market Value will be determined in good faith by the Committee.

 

(x) “Good Reason” means, in the case of a particular Award, unless the applicable Award Agreement or the Participant’s employment agreement with the Company states otherwise, the occurrence of any of the following events, without the express written consent of the Participant: (i) the Company’s material breach of any of its obligations under the Participant’s employment agreement with the Company or the Plan, (ii) reduction in the Participant’s total annual cash compensation opportunity (i.e., base salary and target annual bonus) as described in the Participant’s employment agreement with the Company, (iii) a material relocation of the Participant’s principal place of employment to a location more than fifty (50) miles from the current principal place of employment approved by the Company, or (iv) the failure of a successor to the Company to assume the Company’s obligations under the Participant’s employment agreement with the Company or this Agreement, provided, that, for (i)– (iv) above, the Participant has given written notice to the Company of the condition giving rise to Good Reason within ninety (90) days after its initial occurrence and the Company fails to cure such condition within thirty (30) days following the receipt of such written notification by the Participant to the Company.

 

A-5

 

 

(y) “Immediate Family Members” shall have the meaning set forth in Section 15(b) of the Plan.

 

(z) “Incentive Stock Option” means an Option that is designated by the Committee as an incentive stock option as described in Code Section 422 and otherwise meets the requirements set forth in the Plan.

 

(aa) “Indemnifiable Person” shall have the meaning set forth in Section 4(e) of the Plan.

 

(bb) “Mature Shares” means Common Shares owned by a Participant that are not subject to any pledge or security interest and that have been either previously acquired by the Participant on the open market or meet such other requirements, if any, as the Committee may determine are necessary in order to avoid an accounting earnings charge on account of the use of such shares to pay the Exercise Price or satisfy a tax or deduction obligation of the Participant.

 

(cc) “Nonqualified Stock Option” means an Option that is not designated by the Committee as an Incentive Stock Option.

 

(dd) “Option” means an Award granted under Section 7 of the Plan.

 

(ee) “Option Period” has the meaning given such term in Section 7(c) of the Plan.

 

(ff) “Other Cash-Based Award” shall mean a right or other interest granted to a Participant pursuant to Section 11 of the Plan other than an Other Stock-Based Award.

 

(gg) “Other Stock-Based Award” shall mean a right or other interest granted to a Participant, valued in whole or in part by reference to, or otherwise based on, or related to, Common Stock pursuant to Section 11 of the Plan including but not limited to (i) unrestricted Common Stock awarded as a bonus or upon the attainment of performance goals or otherwise as permitted under the Plan, and (ii) a right granted to a Participant to acquire Common Stock from the Company containing terms and conditions prescribed by the Committee.

 

(hh) “Outstanding Company Common Shares” has the meaning given such term in the definition of “Change in Control.”

 

(ii) “Outstanding Company Voting Securities” has the meaning given such term in the definition of “Change in Control.”

 

(jj) “Participant” means an Eligible Person who has been selected by the Committee to participate in the Plan and to receive an Award pursuant to Section 6 of the Plan.

 

A-6

 

 

(kk) “Performance Compensation Award” shall mean any Award designated by the Committee as a Performance Compensation Award pursuant to Section 11 of the Plan.

 

(ll) “Performance Criteria” shall mean the criterion or criteria that the Committee shall select for purposes of establishing the Performance Goal(s) for a Performance Period with respect to any Performance Compensation Award under the Plan.

 

(mm) “Performance Formula” shall mean, for a Performance Period, the one or more formulae applied against the relevant Performance Goal to determine, with regard to the Performance Compensation Award of a particular Participant, whether all, some portion but less than all, or none of the Performance Compensation Award has been earned for the Performance Period.

 

(nn) “Performance Goals” shall mean, for a Performance Period, the one or more goals established by the Committee for the Performance Period based upon the Performance Criteria.

 

(oo) “Performance Period” shall mean the one or more periods of time, as the Committee may select, over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant’s right to, and the payment of, a Performance Compensation Award.

 

(pp) “Permitted Transferee” shall have the meaning set forth in Section 15(b) of the Plan.

 

(qq) “Person” has the meaning given such term in the definition of “Change in Control.”

 

(rr) “Plan” means this OneMedNet Corporation 2022 Equity Incentive Plan, as amended from time to time.

 

(ss) “Qualifying Termination” means, except as otherwise provided by the Committee as set forth in the Award, the occurrence of either a termination of a Participant’s employment by the Company without Cause or for Good Reason, in either case, occurring on or within the 12-month period (or such other period specified in the applicable Award Agreement) following the consummation of a Change in Control.

 

(tt) “Restricted Period” means the period of time determined by the Committee during which an Award is subject to restrictions or, as applicable, the period of time within which performance is measured for purposes of determining whether an Award has been earned.

 

(uu) “Restricted Stock Unit” means an unfunded and unsecured promise to deliver Common Shares, cash, other securities or other property, subject to certain performance or time-based restrictions (including, without limitation, a requirement that the Participant remain continuously employed or provide continuous services for a specified period of time), granted under Section 9 of the Plan.

 

(vv) “Restricted Stock” means Common Shares, subject to certain specified performance or time-based restrictions (including, without limitation, a requirement that the Participant remain continuously employed or provide continuous services for a specified period of time), granted under Section 9 of the Plan.

 

A-7

 

 

(ww) “Retirement” means, in the case of a particular Award, the definition set forth in the applicable Award Agreement.

 

(xx) “SAR Period” has the meaning given such term in Section 8(c) of the Plan.

 

(yy) “Securities Act” means the Securities Act of 1933, as amended, and any successor thereto. Reference in the Plan to any section of the Securities Act shall be deemed to include any rules, regulations or other interpretative guidance under such section, and any amendments or successor provisions to such section, rules, regulations or guidance.

 

(zz) “Stock Appreciation Right” or “SAR” means an Award granted under Section 8 of the Plan.

 

(aaa) “Stock Bonus Award” means an Award granted under Section 10 of the Plan.

 

(bbb) “Strike Price” means, except as otherwise provided by the Committee in the case of Substitute Awards, (i) in the case of a SAR granted in tandem with an Option, the Exercise Price of the related Option, or (ii) in the case of a SAR granted independent of an Option, the Fair Market Value on the Date of Grant.

 

(ccc) “Subsidiary” means, with respect to any specified Person:

 

(i) any corporation, association or other business entity of which more than 50% of the total voting power of shares (without regard to the occurrence of any contingency and after giving effect to any voting agreement or stockholders’ agreement that effectively transfers voting power) is at the time owned or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of that Person (or a combination thereof); and

 

(ii) any partnership (or any comparable foreign entity (a) the sole general partner (or functional equivalent thereof) or the managing general partner of which is such Person or Subsidiary of such Person or (b) the only general partners (or functional equivalents thereof) of which are that Person or one or more Subsidiaries of that Person (or any combination thereof).

 

(iii) “Substitute Award” has the meaning given such term in Section 5(e) of the Plan.

 

3. Effective Date; Duration. The Plan shall be effective as of the Effective Date. The expiration date of the Plan, on and after which date no Awards may be granted hereunder, shall be the tenth anniversary of the Effective Date; provided, however, that such expiration shall not affect Awards then outstanding, and the terms and conditions of the Plan shall continue to apply to such Awards.

 

4. Administration.

 

(a) The Committee shall administer the Plan. To the extent required to comply with the applicable provisions of Rule 16b-3 promulgated under the Exchange Act (if the Board is not acting as the Committee under the Plan), it is intended that each member of the Committee shall, at the time he or she takes any action with respect to an Award under the Plan, be an Eligible Director. However, the fact that a Committee member shall fail to qualify as an Eligible Director shall not invalidate any Award granted by the Committee that is otherwise validly granted under the Plan.

 

A-8

 

 

(b) Subject to the provisions of the Plan and applicable law, the Committee shall have the sole and plenary authority, in addition to other express powers and authorizations conferred on the Committee by the Plan or by the Board, to: (i) designate Participants; (ii) determine the type or types of Awards to be granted to a Participant; (iii) determine the number of Common Shares to be covered by, or with respect to which payments, rights, or other matters are to be calculated in connection with, Awards; (iv) determine the form of Award Agreement and the terms and conditions of any Award; (v) determine whether, to what extent, and under what circumstances Awards may be settled or exercised in cash, Common Shares, other securities, other Awards or other property, or canceled, forfeited, or suspended and the method or methods by which Awards may be settled, exercised, canceled, forfeited, or suspended; (vi) determine whether, to what extent, and under what circumstances the delivery of cash, Common Shares, other securities, other Awards or other property and other amounts payable with respect to an Award shall be deferred either automatically or at the election of the Participant or of the Committee; (vii) interpret, administer, reconcile any inconsistency in, correct any defect in and/or supply any omission in the Plan and any instrument or agreement relating to, or Award granted under, the Plan; (viii) establish, amend, suspend, or waive any rules and regulations and appoint such agents as the Committee shall deem appropriate for the proper administration of the Plan; (ix) accelerate the vesting or exercisability of, payment for or lapse of restrictions on, Awards, including, but not limited to, upon a Qualifying Termination; (x) to institute and determine the terms and conditions of an Exchange Program; provided, however, that the Committee shall not implement an Exchange Program without the approval of the holders of a majority of the Shares that are present in person or by proxy and entitled to vote at any annual or special meeting of Company’s stockholders; and (xi) make any other determination and take any other action that the Committee deems necessary or desirable for the administration of the Plan.

 

(c) The Committee may delegate to one or more officers of the Company or any Affiliate the authority to act on behalf of the Committee with respect to any matter, right, obligation, or election that is the responsibility of or that is allocated to the Committee herein, and that may be so delegated as a matter of law, except for grants of Awards to persons subject to Section 16 of the Exchange Act.

 

(d) Unless otherwise expressly provided in the Plan, all designations, determinations, interpretations, and other decisions under or with respect to the Plan or any Award or any documents evidencing Awards granted pursuant to the Plan shall be within the sole discretion of the Committee, may be made at any time and shall be final, conclusive and binding upon all persons or entities, including, without limitation, the Company, any Affiliate, any Participant, any holder or beneficiary of any Award, and any stockholder of the Company.

 

A-9

 

 

(e) No member of the Board, the Committee, delegate of the Committee or any employee or agent of the Company (each such person, an “Indemnifiable Person”) shall be liable for any action taken or omitted to be taken or any determination made in good faith with respect to the Plan or any Award hereunder. Each Indemnifiable Person shall be indemnified and held harmless by the Company against and from any loss, cost, liability, or expense (including attorneys’ fees) that may be imposed upon or incurred by such Indemnifiable Person in connection with or resulting from any action, suit or proceeding to which such Indemnifiable Person may be a party or in which such Indemnifiable Person may be involved by reason of any action taken or omitted to be taken under the Plan or any Award Agreement and against and from any and all amounts paid by such Indemnifiable Person with the Company’s approval, in settlement thereof, or paid by such Indemnifiable Person in satisfaction of any judgment in any such action, suit or proceeding against such Indemnifiable Person, provided that the Company shall have the right, at its own expense, to assume and defend any such action, suit or proceeding and once the Company gives notice of its intent to assume the defense, the Company shall have sole control over such defense with counsel of the Company’s choice. The foregoing right of indemnification shall not be available to an Indemnifiable Person to the extent that a final judgment or other final adjudication (in either case not subject to further appeal) binding upon such Indemnifiable Person determines that the acts or omissions of such Indemnifiable Person giving rise to the indemnification claim resulted from such Indemnifiable Person’s bad faith, fraud or willful criminal act or omission or that such right of indemnification is otherwise prohibited by law or by the Company’s Articles of Incorporation or Bylaws. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such Indemnifiable Persons may be entitled under the Company’s Articles of Incorporation or Bylaws, as a matter of law, or otherwise, or any other power that the Company may have to indemnify such Indemnifiable Persons or hold them harmless.

 

(f) Notwithstanding anything to the contrary contained in the Plan, the Board may, in its sole discretion, at any time and from time to time, grant Awards and administer the Plan with respect to such Awards. In any such case, the Board shall have all the authority granted to the Committee under the Plan.

 

5. Grant of Awards; Shares Subject to the Plan; Limitations.

 

(a) The Committee may, from time to time, grant Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Stock Bonus Awards and/or Performance Compensation Awards to one or more Eligible Persons.

 

(b) Subject to Section 13 of the Plan, Awards granted under the Plan shall be subject to the following limitations: (i) the Committee is authorized to deliver under the Plan an aggregate of 335,722 Common Shares; provided, that total number of Common Shares that will be reserved, and that may be issued, under the Plan will automatically increase on the first trading day of each calendar year, beginning with calendar year 2023, by a number of Common Shares equal to five percent (5%) of the total outstanding Common Shares on the last day of the prior calendar year (subject to a maximum annual increase of 100,000 Common Shares), (ii) in no event shall the maximum aggregate number of Common Shares that may be issued under the Plan pursuant to Incentive Stock Options exceed the aggregate number of Common Shares set forth in Section 5(b)(i) of the Plan plus, to the extent allowable under Code Section 422 and the regulations promulgated thereunder, any Common Shares that again become available for issuance pursuant to Section 5(c) of the Plan and (iii) the maximum number of Common Shares that may be granted under the Plan during any single fiscal year to any Participant who is a non-employee director, when taken together with any cash fees paid to such non-employee director during such year in respect of his or her service as a non-employee director (including service as a member or chair of any committee of the Board), shall not exceed $750,000 in total value (calculating the value of any such Awards based on the grant date fair value of such Awards for financial reporting purposes); provided that the non-employee directors who are considered independent (under the rules of The NASDAQ Stock Market or other securities exchange on which the Common Shares are traded) may make exceptions to this limit for a non-executive chair of the Board, if any, in which case the non-employee Director receiving such additional compensation may not participate in the decision to award such compensation. Notwithstanding the automatic annual increase set forth in (i) above, the Board may act prior to January 1st of a given year to provide that there will be no such increase in the share reserve for such year or that the increase in the share reserve for such year will be a lesser number of Common Shares than would otherwise occur pursuant to the stipulated percentage.

 

A-10

 

 

(c) In the event that (i) any Option or other Award granted hereunder is exercised through the tendering of Common Shares (either actually or by attestation) or by the withholding of Common Shares by the Company, or (ii) tax or deduction liabilities arising from such Option or other Award are satisfied by the tendering of Common Shares (either actually or by attestation) or by the withholding of Common Shares by the Company, then in each such case the Common Shares so tendered or withheld shall be added to the Common Shares available for grant under the Plan on a one-for-one basis. Shares underlying Awards under this Plan that are forfeited, cancelled, expire unexercised, or are settled in cash are available again for Awards under the Plan.

 

(d) Common Shares delivered by the Company in settlement of Awards may be authorized and unissued shares, shares held in the treasury of the Company, shares purchased on the open market or by private purchase, or a combination of the foregoing.

 

(e) Awards may, in the sole discretion of the Committee, be granted under the Plan in assumption of, or in substitution for, outstanding awards previously granted by an entity acquired by the Company or with which the Company combines (“Substitute Awards”). The number of Common Shares underlying any Substitute Awards shall not be counted against the aggregate number of Common Shares available for Awards under the Plan.

 

6. Eligibility. Participation shall be limited to Eligible Persons who have entered into an Award Agreement or who have received written notification from the Committee, or from a person designated by the Committee, that they have been selected to participate in the Plan.

 

7. Options.

 

(a) Generally. Each Option granted under the Plan shall be evidenced by an Award Agreement (whether in paper or electronic medium (including email or the posting on a web site maintained by the Company or a third party under contract with the Company)). Each Option so granted shall be subject to the conditions set forth in this Section 7, and to such other conditions not inconsistent with the Plan as may be reflected in the applicable Award Agreement. All Options granted under the Plan shall be Nonqualified Stock Options unless the applicable Award Agreement expressly states that the Option is intended to be an Incentive Stock Option. Incentive Stock Options shall be granted only to Eligible Persons who are employees of the Company and its Affiliates, and no Incentive Stock Option shall be granted to any Eligible Person who is ineligible to receive an Incentive Stock Option under the Code. No Option shall be treated as an Incentive Stock Option unless the Plan has been approved by the stockholders of the Company in a manner intended to comply with the stockholder approval requirements of Code Section 422(b)(1); provided that any Option intended to be an Incentive Stock Option shall not fail to be effective solely on account of a failure to obtain such approval, but rather such Option shall be treated as a Nonqualified Stock Option unless and until such approval is obtained. In the case of an Incentive Stock Option, the terms and conditions of such grant shall be subject to and comply with such rules as may be prescribed by Code Section 422. If for any reason an Option intended to be an Incentive Stock Option (or any portion thereof) shall not qualify as an Incentive Stock Option, then, to the extent of such non-qualification, such Option or portion thereof shall be regarded as a Nonqualified Stock Option appropriately granted under the Plan.

 

A-11

 

 

(b) Exercise Price. Except with respect to Substitute Awards, the exercise price (“Exercise Price”) per Common Share for each Option shall not be less than 100% of the Fair Market Value of such share determined as of the Date of Grant; provided, however, that in the case of an Incentive Stock Option granted to an employee who, at the time of the grant of such Option, owns shares representing more than 10% of the total combined voting power of all classes of shares of the Company or any related corporation (as determined in accordance with Treasury Regulation Section 1.422-2(f)), the Exercise Price per share shall not be less than 110% of the Fair Market Value per share on the Date of Grant and provided further, that, notwithstanding any provision herein to the contrary, the Exercise Price shall not be less than the par value per Common Share.

 

(c) Vesting and Expiration. Options shall vest and become exercisable in such manner and on such date or dates determined by the Committee and shall expire after such period, not to exceed ten years, as may be determined by the Committee (the “Option Period”); provided, however, that the Option Period shall not exceed five years from the Date of Grant in the case of an Incentive Stock Option granted to a Participant who on the Date of Grant owns shares representing more than 10% of the total combined voting power of all classes of shares of the Company or any related corporation (as determined in accordance with Treasury Regulation Section 1.422-2(f)); provided, further, that notwithstanding any vesting dates set by the Committee, the Committee may, in its sole discretion, accelerate the exercisability of any Option, which acceleration shall not affect the terms and conditions of such Option other than with respect to exercisability. Unless otherwise provided by the Committee in an Award Agreement: (i) the unvested portion of an Option shall expire upon termination of employment or service of the Participant granted the Option, and the vested portion of such Option shall remain exercisable for (A) one year following termination of employment or service by reason of such Participant’s death or disability (as determined by the Committee), but not later than the expiration of the Option Period or (B) ninety (90) days following termination of employment or service for any reason other than such Participant’s death or disability, and other than such Participant’s termination of employment or service for Cause, but not later than the expiration of the Option Period; and (ii) both the unvested and the vested portion of an Option shall expire upon the termination of the Participant’s employment or service by the Company for Cause. If the Option would expire at a time when the exercise of the Option would violate applicable securities laws, the expiration date applicable to the Option will be automatically extended to a date that is thirty (30) calendar days following the date such exercise would no longer violate applicable securities laws (so long as such extension shall not violate Code Section 409A); provided, that in no event shall such expiration date be extended beyond the expiration of the Option Period.

 

(d) Method of Exercise and Form of Payment. No Common Shares shall be delivered pursuant to any exercise of an Option until payment in full of the Exercise Price therefor is received by the Company and the Participant has paid to the Company an amount equal to any taxes required to be withheld or paid. Options that have become exercisable may be exercised by delivery of written or electronic notice of exercise to the Company in accordance with the terms of the Option accompanied by payment of the Exercise Price. The Exercise Price shall be payable (i) in cash, check, cash equivalent and/or Common Shares valued at the fair market value at the time the Option is exercised (including, pursuant to procedures approved by the Committee, by means of attestation of ownership of a sufficient number of Common Shares in lieu of actual delivery of such shares to the Company); provided that such Common Shares are not subject to any pledge or other security interest and are Mature Shares and; (ii) by such other method as the Committee may permit in accordance with applicable law, in its sole discretion, on a case by case basis, including without limitation: (A) in other property having a fair market value on the date of exercise equal to the Exercise Price or (B) if there is a public market for the Common Shares at such time, by means of a broker-assisted “cashless exercise” pursuant to which the Company is delivered a copy of irrevocable instructions to a stockbroker to sell the Common Shares otherwise deliverable upon the exercise of the Option and to deliver promptly to the Company an amount equal to the Exercise Price or (C) by a “net exercise” method whereby the Company withholds from the delivery of the Common Shares for which the Option was exercised that number of Common Shares having a fair market value equal to the aggregate Exercise Price for the Common Shares for which the Option was exercised. No fractional Common Shares shall be issued or delivered pursuant to the Plan or any Award, and the Committee shall determine whether cash, other securities or other property shall be paid or transferred in lieu of any fractional Common Shares, or whether such fractional Common Shares or any rights thereto shall be canceled, terminated or otherwise eliminated.

 

A-12

 

 

(e) Notification upon Disqualifying Disposition of an Incentive Stock Option. Each Participant awarded an Incentive Stock Option under the Plan shall notify the Company in writing immediately after the date he makes a disqualifying disposition of any Common Shares acquired pursuant to the exercise of such Incentive Stock Option. A disqualifying disposition is any disposition (including, without limitation, any sale) of such Common Shares before the later of (A) two (2) years after the Date of Grant of the Incentive Stock Option or (B) one (1) year after the date of exercise of the Incentive Stock Option. The Company may, if determined by the Committee and in accordance with procedures established by the Committee, retain possession of any Common Shares acquired pursuant to the exercise of an Incentive Stock Option as agent for the applicable Participant until the end of the period described in the preceding sentence.

 

(f) Compliance with Laws, etc. Notwithstanding the foregoing, in no event shall a Participant be permitted to exercise an Option in a manner that the Committee determines would violate the Sarbanes-Oxley Act of 2002, if applicable, or any other applicable law or the applicable rules and regulations of the Securities and Exchange Commission or the applicable rules and regulations of any securities exchange or inter-dealer quotation system on which the securities of the Company are listed or traded.

 

8. Stock Appreciation Rights.

 

(a) Generally. Each SAR granted under the Plan shall be evidenced by an Award Agreement (whether in paper or electronic medium (including email or the posting on a web site maintained by the Company or a third party under contract with the Company)). Each SAR so granted shall be subject to the conditions set forth in this Section 8, and to such other conditions not inconsistent with the Plan as may be reflected in the applicable Award Agreement. Any Option granted under the Plan may include tandem SARs. The Committee also may award SARs to Eligible Persons independent of any Option.

 

(b) Exercise Price. The Exercise Price per Common Share for each SAR shall not be less than 100% of the Fair Market Value of such share determined as of the Date of Grant.

 

(c) Vesting and Expiration. A SAR granted in connection with an Option shall become exercisable and shall expire according to the same vesting schedule and expiration provisions as the corresponding Option. A SAR granted independent of an Option shall vest and become exercisable and shall expire in such manner and on such date or dates determined by the Committee and shall expire after such period, not to exceed ten years, as may be determined by the Committee (the “SAR Period”); provided, however, that notwithstanding any vesting dates set by the Committee, the Committee may, in its sole discretion, accelerate the exercisability of any SAR, which acceleration shall not affect the terms and conditions of such SAR other than with respect to exercisability. Unless otherwise provided by the Committee in an Award Agreement: (i) the unvested portion of a SAR shall expire upon termination of employment or service of the Participant granted the SAR, and the vested portion of such SAR shall remain exercisable for (A) one year following termination of employment or service by reason of such Participant’s death or disability (as determined by the Committee), but not later than the expiration of the SAR Period or (B) 90 days following termination of employment or service for any reason other than such Participant’s death or disability, and other than such Participant’s termination of employment or service for Cause, but not later than the expiration of the SAR Period; and (ii) both the unvested and the vested portion of a SAR shall expire upon the termination of the Participant’s employment or service by the Company for Cause. If the SAR would expire at a time when the exercise of the SAR would violate applicable securities laws, the expiration date applicable to the SAR will be automatically extended to a date that is thirty (30) calendar days following the date such exercise would no longer violate applicable securities laws (so long as such extension shall not violate Code Section 409A); provided, that in no event shall such expiration date be extended beyond the expiration of the SAR Period.

 

(d) Method of Exercise. SARs that have become exercisable may be exercised by delivery of written or electronic notice of exercise to the Company in accordance with the terms of the Award, specifying the number of SARs to be exercised and the date on which such SARs were awarded. Notwithstanding the foregoing, if on the last day of the Option Period (or in the case of a SAR independent of an option, the SAR Period), the fair market value exceeds the Strike Price, the Participant has not exercised the SAR or the corresponding Option (if applicable), and neither the SAR nor the corresponding Option (if applicable) has expired, such SAR shall be deemed to have been exercised by the Participant on such last day and the Company shall make the appropriate payment therefor.

 

A-13

 

 

(e) Payment. Upon the exercise of a SAR, the Company shall pay to the Participant an amount equal to the number of shares subject to the SAR that are being exercised multiplied by the excess, if any, of the fair market value of one Common Share on the exercise date over the Strike Price, less an amount equal to any taxes required to be withheld or paid. The Company shall pay such amount in cash, in Common Shares valued at fair market value, or any combination thereof, as determined by the Committee. No fractional Common Shares shall be issued or delivered pursuant to the Plan or any Award, and the Committee shall determine whether cash, other securities or other property shall be paid or transferred in lieu of any fractional Common Shares, or whether such fractional Common Shares or any rights thereto shall be canceled, terminated or otherwise eliminated.

 

9. Restricted Stock and Restricted Stock Units.

 

(a) Generally. Each grant of Restricted Stock and Restricted Stock Units shall be evidenced by an Award Agreement (whether in paper or electronic medium (including email or the posting on a web site maintained by the Company or a third party under contract with the Company)). Each such grant shall be subject to the conditions set forth in this Section 9, and to such other conditions not inconsistent with the Plan as may be reflected in the applicable Award Agreement.

 

(b) Restricted Accounts; Escrow or Similar Arrangement. Upon the grant of Restricted Stock, a book entry in a restricted account shall be established in the Participant’s name at the Company’s transfer agent and, if the Committee determines that the Restricted Stock shall be held by the Company or in escrow rather than held in such restricted account pending the release of the applicable restrictions, the Committee may require the Participant to additionally execute and deliver to the Company (i) an escrow agreement satisfactory to the Committee, if applicable, and (ii) the appropriate share power (endorsed in blank) with respect to the Restricted Stock covered by such agreement. If a Participant shall fail to execute an agreement evidencing an Award of Restricted Stock and, if applicable, an escrow agreement and blank share power within the amount of time specified by the Committee, the Award shall be null and void. Subject to the restrictions set forth in this Section 9 and the applicable Award Agreement, the Participant generally shall have the rights and privileges of a stockholder as to such Restricted Stock, including without limitation the right to vote such Restricted Stock and the right to receive dividends, if applicable. To the extent shares of Restricted Stock are forfeited, any share certificates issued to the Participant evidencing such shares shall be returned to the Company, and all rights of the Participant to such shares and as a stockholder with respect thereto shall terminate without further obligation on the part of the Company.

 

(c) Vesting; Acceleration of Lapse of Restrictions. Unless otherwise provided by the Committee in an Award Agreement the unvested portion of Restricted Stock and Restricted Stock Units shall terminate and be forfeited upon termination of employment or service of the Participant granted the applicable Award.

 

A-14

 

 

(d) Delivery of Restricted Stock and Settlement of Restricted Stock Units.

 

(i) Upon the expiration of the Restricted Period with respect to any shares of Restricted Stock, the restrictions set forth in the applicable Award Agreement shall be of no further force or effect with respect to such shares, except as set forth in the applicable Award Agreement. If an escrow arrangement is used, upon such expiration, the Company shall deliver to the Participant, or his beneficiary, without charge, the share certificate evidencing the shares of Restricted Stock that have not then been forfeited and with respect to which the Restricted Period has expired (rounded down to the nearest full share). Dividends, if any, that may have been withheld by the Committee and attributable to any particular share of Restricted Stock shall be distributed to the Committee and attributable to any particular share of Restricted Stock shall be distributed to the Participant in cash or, at the sole discretion of the Committee, in Common Shares having a fair market value equal to the amount of such dividends, upon the release of restrictions on such share and, if such share is forfeited, the Participant shall have no right to such dividends (except as otherwise set forth by the Committee in the applicable Award Agreement).

 

(ii) Unless otherwise provided by the Committee in an Award Agreement, upon the expiration of the Restricted Period with respect to any outstanding Restricted Stock Units, the Company shall deliver to the Participant, or his beneficiary, without charge, one Common Share for each such outstanding Restricted Stock Unit; provided, however, that the Committee may, in its sole discretion, elect to (i) pay cash or part cash and part Common Share in lieu of delivering only Common Shares in respect of such Restricted Stock Units or (ii) defer the delivery of Common Shares (or cash or part Common Shares and part cash, as the case may be) beyond the expiration of the Restricted Period if such delivery would result in a violation of applicable law until such time as is no longer the case. If a cash payment is made in lieu of delivering Common Shares, the amount of such payment shall be equal to the fair market value of the Common Shares as of the date on which the Restricted Period lapsed with respect to such Restricted Stock Units, less an amount equal to any taxes required to be withheld or paid.

 

10. Stock Bonus Awards. The Committee may issue unrestricted Common Shares, or other Awards denominated in Common Shares, under the Plan to Eligible Persons, either alone or in tandem with other awards, in such amounts as the Committee shall from time to time in its sole discretion determine. Each Stock Bonus Award granted under the Plan shall be evidenced by an Award Agreement (whether in paper or electronic medium (including email or the posting on a web site maintained by the Company or a third party under contract with the Company)). Each Stock Bonus Award so granted shall be subject to such conditions not inconsistent with the Plan as may be reflected in the applicable Award Agreement.

 

11. Performance Compensation Awards.

 

(a) Generally. The Committee shall have the authority, at the time of grant of any Award described in Sections 7 through 10 of the Plan, to designate such Award as a Performance Compensation Award. The Committee shall have the authority to make an award of a cash bonus to any Participant and designate such Award as a Performance Compensation Award. Unless otherwise determined by the Committee, all Performance Compensation Awards shall be evidenced by an Award Agreement.

 

(b) Discretion of Committee with Respect to Performance Compensation Awards. The Committee shall have the discretion to establish the terms, conditions and restrictions of any Performance Compensation Award. With regard to a particular Performance Period, the Committee shall have sole discretion to select the length of such Performance Period, the type(s) of Performance Compensation Awards to be issued, the Performance Criteria that will be used to establish the Performance Goal (s), the kind(s) and/or level(s) of the Performance Goals(s) that is (are) to apply and the Performance Formula.

 

A-15

 

 

(c) Performance Criteria. The Committee may establish Performance Criteria that will be used to establish the Performance Goal(s) for Performance Compensation Awards which may be based on the attainment of specific levels of performance of the Company (and/or one or more Affiliates, divisions, business segments or operational units, or any combination of the foregoing) and may include, without limitation, any of the following: (i) net earnings or net income (before or after taxes); (ii) basic or diluted earnings per share (before or after taxes); (iii) revenue or revenue growth (measured on a net or gross basis); (iv) gross profit or gross profit growth; (v) operating profit (before or after taxes); (vi) return measures (including, but not limited to, return on assets, capital, invested capital, equity, or sales); (vii) cash flow (including, but not limited to, operating cash flow, free cash flow, net cash provided by operations and cash flow return on capital); (viii) financing and other capital raising transactions (including, but not limited to, sales of the Company’s equity or debt securities); (ix) earnings before or after taxes, interest, depreciation and/or amortization; (x) gross or operating margins; (xi) productivity ratios; (xii) share price (including, but not limited to, growth measures and total stockholder return); (xiii) expense targets; (xiv) margins; (xv) productivity and operating efficiencies; (xvi) customer satisfaction; (xvii) customer growth; (xviii) working capital targets; (xix) measures of economic value added; (xx) inventory control; (xxi) enterprise value; (xxii) sales; (xxiii) debt levels and net debt; (xxiv) combined ratio; (xxv) timely launch of new facilities; (xxvi) client retention; (xxvii) employee retention; (xxviii) timely completion of rollouts of new products and services; (xxix) cost targets; (xxx) reductions and savings; (xxxi) productivity and efficiencies; (xxxii) strategic partnerships or transactions; and (xxxiii) personal targets, goals or completion of projects. Any one or more of the Performance Criteria may be used on an absolute or relative basis to measure the performance of the Company and/or one or more Affiliates as a whole or any business unit(s) of the Company and/or one or more Affiliates or any combination thereof, as the Committee may deem appropriate, or any of the above Performance Criteria may be compared to the performance of a selected group of comparison or peer companies, or a published or special index that the Committee, in its sole discretion, deems appropriate, or as compared to various stock market indices. The Committee also has the authority to provide for accelerated vesting of any Award based on the achievement of Performance Goals pursuant to the Performance Criteria specified in this paragraph. Any Performance Criteria that are financial metrics, may be determined in accordance with United States Generally Accepted Accounting Principles (“GAAP”) or may be adjusted when established to include or exclude any items otherwise includable or excludable under GAAP.

 

(d) Modification of Performance Goal(s). The Committee is authorized at any time to adjust or modify the calculation of a Performance Goal for such Performance Period, based on and in order to appropriately reflect any specified circumstance or event that occurs during a Performance Period, including but not limited to the following: (i) asset write-downs; (ii) litigation or claim judgments or settlements; (iii) the effect of changes in tax laws, accounting principles, or other laws or regulatory rules affecting reported results; (iv) any reorganization and restructuring programs; (v) unusual and/or infrequently occurring items as described in Accounting Principles Board Opinion No. 30 (or any successor pronouncement thereto) and/or in management’s discussion and analysis of financial condition and results of operations appearing in the Company’s annual report to stockholders for the applicable year; (vi) acquisitions or divestitures; (vii) discontinued operations; (viii) any other specific unusual or infrequently occurring or non-recurring events, or objectively determinable category thereof; (ix) foreign exchange gains and losses; and (x) a change in the Company’s fiscal year.

 

A-16

 

 

(e) Terms and Conditions to Receipt of Payment. Unless otherwise provided in the applicable Award Agreement, a Participant must be employed by the Company on the last day of a Performance Period to be eligible for payment in respect of a Performance Compensation Award for such Performance Period. A Participant shall be eligible to receive payment in respect of a Performance Compensation Award only to the extent that: (A) the Performance Goals for such period are achieved; and (B) all or some of the portion of such Participant’s Performance Compensation Award has been earned for the Performance Period based on the application of the Performance Formula to such achieved Performance Goals. Following the completion of a Performance Period, the Committee shall determine whether, and to what extent, the Performance Goals for the Performance Period have been achieved and, if so, calculate the amount of the Performance Compensation Awards earned for the period based upon the Performance Formula. The Committee shall then determine the amount of each Participant’s Performance Compensation Award actually payable for the Performance Period.

 

(f) Timing of Award Payments. Except as provided in an Award Agreement, Performance Compensation Awards granted for a Performance Period shall be paid to Participants as soon as administratively practicable following the Committee’s determination in accordance with Section 11(e).

 

12. Other Stock-or Cash-Based Awards. The Committee is authorized to grant Awards to Participants in the form of Other Stock-Based Awards or Other Cash-Based Awards, as deemed by the Committee to be consistent with the purposes of the Plan. To the extent necessary to satisfy the short-term deferral exception to Code Section 409A, unless the Committee shall determine otherwise, the Awards shall provide that payment shall be made within 2 1∕2 months after the end of the year in which the Participant has a legally binding vested right to such Award. The Committee may establish such other rules applicable to the Other Stock- or Cash-Based Awards as it deems appropriate, to the extent not inconsistent with the Plan.

 

13. Changes in Capital Structure and Similar Events. In the event of (i) any dividend (other than ordinary cash dividends) or other distribution (whether in the form of cash, Common Shares, other securities or other property), recapitalization, stock split, reverse stock split, reorganization, merger, amalgamation, consolidation, spin-off, split-up, split-off, combination, repurchase or exchange of Common Shares or other securities of the Company, issuance of warrants or other rights to acquire Common Shares or other securities of the Company, or other similar corporate transaction or event (including, without limitation, a Change in Control) that affects the Common Shares, or (ii) unusual or infrequently occurring events (including, without limitation, a Change in Control) affecting the Company, any Affiliate, or the financial statements of the Company or any Affiliate, or changes in applicable rules, rulings, regulations or other requirements of any governmental body or securities exchange or inter-dealer quotation system, accounting principles or law, such that in either case an adjustment is determined by the Committee in its sole discretion to be necessary or appropriate, then the Committee shall make any such adjustments in such manner as it may deem equitable, including without limitation any or all of the following:

 

(a) adjusting any or all of (A) the number of Common Shares or other securities of the Company (or number and kind of other securities or other property) that may be delivered in respect of Awards or with respect to which Awards may be granted under the Plan (including, without limitation, adjusting any or all of the limitations under Section 5 of the Plan) and (B) the terms of any outstanding Award, including, without limitation, (1) the number of Common Shares or other securities of the Company (or number and kind of other securities or other property) subject to outstanding Awards or to which outstanding Awards relate, (2) the Exercise Price or Strike Price with respect to any Award or (3) any applicable performance measures (including, without limitation, Performance Criteria and Performance Goals);

 

A-17

 

 

(b) providing for a substitution or assumption of Awards in a manner that substantially preserves the applicable terms of such Awards;

 

(c) accelerating the exercisability or vesting of, lapse of restrictions on, or termination of, Awards or providing for a period of time for exercise prior to the occurrence of such event;

 

(d) modifying the terms of Awards to add events, conditions or circumstances (including termination of employment within a specified period after a Change in Control) upon which the exercisability or vesting of or lapse of restrictions thereon will accelerate;

 

(e) deeming any performance measures (including, without limitation, Performance Criteria and Performance Goals) satisfied at target, maximum or actual performance through closing or such other level determined by the Committee in its sole discretion, or providing for the performance measures to continue (as is or as adjusted by the Committee) after closing;

 

(f) providing that for a period prior to the Change in Control determined by the Committee in its sole discretion, any Options or SARs that would not otherwise become exercisable prior to the Change in Control will be exercisable as to all Common Shares subject thereto (but any such exercise will be contingent upon and subject to the occurrence of the Change in Control and if the Change in Control does not take place after giving such notice for any reason whatsoever, the exercise will be null and void) and that any Options or SARs not exercised prior to the consummation of the Change in Control will terminate and be of no further force and effect as of the consummation of the Change in Control; and

 

(g) canceling any one or more outstanding Awards and causing to be paid to the holders thereof, in cash, Common Shares, other securities or other property, or any combination thereof, the value of such Awards, if any, as determined by the Committee (which if applicable may be based upon the price per Common Share received or to be received by other stockholders of the Company in such event), including without limitation, in the case of an outstanding Option or SAR, a cash payment in an amount equal to the excess, if any, of the fair market value (as of a date specified by the Committee) of the Common Shares subject to such Option or SAR over the aggregate Exercise Price or Strike Price of such Option or SAR, respectively (it being understood that, in such event, any Option or SAR having a per share Exercise Price or Strike Price equal to, or in excess of, the fair market value of a Common Share subject thereto may be canceled and terminated without any payment or consideration therefor); provided, however, that in the case of any “equity restructuring” (within the meaning of the Financial Accounting Standards Board Accounting Standards Codification Topic 718), the Committee shall make an equitable or proportionate adjustment to outstanding Awards to reflect such equity restructuring. The Company shall give each Participant notice of an adjustment hereunder and, upon notice, such adjustment shall be conclusive and binding for all purposes.

 

A-18

 

 

14. Amendments and Termination.

 

(a) Amendment and Termination of the Plan. The Board may amend, alter, suspend, discontinue, or terminate the Plan or any portion thereof at any time; provided that (i) no amendment to Section 14(b) (to the extent required by the proviso in such Section 14(b)) shall be made without stockholder approval and (ii) no such amendment, alteration, suspension, discontinuation or termination shall be made without stockholder approval if such approval is necessary to comply with any tax or regulatory requirement applicable to the Plan (including, without limitation, as necessary to comply with any rules or requirements of any securities exchange or inter-dealer quotation system on which the Common Shares may be listed or quoted); provided, further, that any such amendment, alteration, suspension, discontinuance or termination that would materially and adversely affect the rights of any Participant or any holder or beneficiary of any Award theretofore granted shall not to that extent be effective without the consent of the affected Participant, holder or beneficiary.

 

(b) Amendment of Award Agreements. The Committee may, to the extent consistent with the terms of any applicable Award Agreement, waive any conditions or rights under, amend any terms of, or alter, suspend, discontinue, cancel or terminate, any Award theretofore granted or the associated Award Agreement, prospectively or retroactively; provided that any such waiver, amendment, alteration, suspension, discontinuance, cancellation or termination that would materially and adversely affect the rights of any Participant with respect to any Award theretofore granted shall not to that extent be effective without the consent of the affected Participant; provided, further, that without stockholder approval, except as otherwise permitted under Section 13 of the Plan, (i) no amendment or modification may reduce the Exercise Price of any Option or the Strike Price of any SAR, (ii) the Committee may not cancel any outstanding Option or SAR where the Fair Market Value of the Common Shares underlying such Option or SAR is less than its Exercise Price and replace it with a new Option or SAR, another Award or cash and (iii) the Committee may not take any other action that is considered a “repricing” for purposes of the stockholder approval rules of the applicable securities exchange or inter-dealer quotation system on which the Common Shares are listed or quoted.

 

15. General.

 

(a) Award Agreements. Each Award under the Plan shall be evidenced by an Award Agreement, which shall be delivered to the Participant (whether in paper or electronic medium (including email or the posting on a web site maintained by the Company or a third party under contract with the Company)) and shall specify the terms and conditions of the Award and any rules applicable thereto, including without limitation, the effect on such Award of the death, disability or termination of employment or service of a Participant, or of such other events as may be determined by the Committee.

 

A-19

 

 

(b) Nontransferability.

 

(i) Each Award shall be exercisable only by a Participant during the Participant’s lifetime, or, if permissible under applicable law, by the Participant’s legal guardian or representative. No Award may be assigned, alienated, pledged, attached, sold or otherwise transferred or encumbered by a Participant other than by will or by the laws of descent and distribution and any such purported assignment, alienation, pledge, attachment, sale, transfer or encumbrance shall be void and unenforceable against the Company or an Affiliate; provided that the designation of a beneficiary shall not constitute an assignment, alienation, pledge, attachment, sale, transfer or encumbrance.

 

(ii) Notwithstanding the foregoing, the Committee may, in its sole discretion, permit Awards (other than Incentive Stock Options) to be transferred by a Participant, without consideration, subject to such rules as the Committee may adopt consistent with any applicable Award Agreement to preserve the purposes of the Plan, to: (A) any person who is a “family member” of the Participant, as such term is used in the instructions to Form S-8 under the Securities Act (collectively, the “Immediate Family Members”); (B) a trust solely for the benefit of the Participant and his or her Immediate Family Members; (C) a partnership or limited liability company whose only partners or stockholders are the Participant and his or her Immediate Family Members; or (D) any other transferee as may be approved either (I) by the Board or the Committee in its sole discretion, or (II) as provided in the applicable Award Agreement (each transferee described in clauses (A), (B), (C) and (D) above is hereinafter referred to as a “Permitted Transferee”); provided that the Participant gives the Committee advance written notice describing the terms and conditions of the proposed transfer and the Committee notifies the Participant in writing that such a transfer would comply with the requirements of the Plan.

 

(iii) The terms of any Award transferred in accordance with the immediately preceding sentence shall apply to the Permitted Transferee and any reference in the Plan, or in any applicable Award Agreement, to a Participant shall be deemed to refer to the Permitted Transferee, except that (A) Permitted Transferees shall not be entitled to transfer any Award, other than by will or the laws of descent and distribution; (B) Permitted Transferees shall not be entitled to exercise any transferred Option unless there shall be in effect a registration statement on an appropriate form covering the Common Shares to be acquired pursuant to the exercise of such Option if the Committee determines, consistent with any applicable Award Agreement, that such a registration statement is necessary or appropriate; (C) the Committee or the Company shall not be required to provide any notice to a Permitted Transferee, whether or not such notice is or would otherwise have been required to be given to the Participant under the Plan or otherwise; and (D) the consequences of the termination of the Participant’s employment by, or services to, the Company or an Affiliate under the terms of the Plan and the applicable Award Agreement shall continue to be applied with respect to the Participant, including, without limitation, that an Option shall be exercisable by the Permitted Transferee only to the extent, and for the periods, specified in the Plan and the applicable Award Agreement.

 

A-20

 

 

(c) Tax Withholding and Deductions.

 

(i) A Participant shall be required to pay to the Company or any Affiliate, and the Company or any Affiliate shall have the right and is hereby authorized to deduct and withhold, from any cash, Common Shares, other securities or other property deliverable under any Award or from any compensation or other amounts owing to a Participant, the amount (in cash, Common Shares, other securities or other property) of any required taxes (up to the maximum statutory rate under applicable law as in effect from time to time as determined by the Committee) and deduction in respect of an Award, its grant, vesting or exercise, or any payment or transfer under an Award or under the Plan and to take such other action as may be necessary in the opinion of the Committee or the Company to satisfy all obligations for the payment of such taxes.

 

(ii) Without limiting the generality of clause (i) above, the Committee may, in its sole discretion, determined on a case by case basis, permit a Participant to satisfy, in whole or in part, the foregoing tax and deduction liability by (A) the delivery of Common Shares (which are not subject to any pledge or other security interest and are Mature Shares, except as otherwise determined by the Committee) owned by the Participant having a fair market value equal to such liability or (B) having the Company withhold from the number of Common Shares otherwise issuable or deliverable pursuant to the exercise or settlement of the Award a number of shares with a fair market value equal to such liability.

 

(d) No Claim to Awards; No Rights to Continued Employment; Waiver. No employee of the Company or an Affiliate, or other person, shall have any claim or right to be granted an Award under the Plan or, having been selected for the grant of an Award, to be selected for a grant of any other Award. There is no obligation for uniformity of treatment of Participants or holders or beneficiaries of Awards. The terms and conditions of Awards and the Committee’s determinations and interpretations with respect thereto need not be the same with respect to each Participant and may be made selectively among Participants, whether or not such Participants are similarly situated. Neither the Plan nor any action taken hereunder shall be construed as giving any Participant any right to be retained in the employ or service of the Company or an Affiliate, nor shall it be construed as giving any Participant any rights to continued service on the Board. The Company or any of its Affiliates may at any time dismiss a Participant from employment or discontinue any consulting relationship, free from any liability or any claim under the Plan, unless otherwise expressly provided in the Plan or any Award Agreement. By accepting an Award under the Plan, a Participant shall thereby be deemed to have waived any claim to continued exercise or vesting of an Award or to damages or severance entitlement related to non-continuation of the Award beyond the period provided under the Plan or any Award Agreement, notwithstanding any provision to the contrary in any written employment contract or other agreement between the Company and its Affiliates and the Participant, whether any such agreement is executed before, on or after the Date of Grant.

 

(e) Addenda/International Participants. The Committee may adopt such addenda to the Plan as it may consider necessary or appropriate for the purpose of granting Awards, which Awards may contain such terms and conditions as the Committee deems necessary or appropriate to accommodate differences in local law, tax policy or custom, which may deviate from the terms and conditions set forth in this Plan. The terms of any such addenda shall supersede the terms of the Plan to the extent necessary to accommodate such differences but shall not otherwise affect the terms of the Plan as in effect for any other purpose. With respect to Participants who reside or work outside of the United States of America, the Committee may in its sole discretion amend the terms of the Plan or outstanding Awards with respect to such Participants in order to conform such terms with the requirements of local law or to obtain more favorable tax or other treatment for a Participant, the Company or its Affiliates.

 

A-21

 

 

(f) Designation and Change of Beneficiary. Each Participant may file with the Committee a written designation of one or more persons as the beneficiary(ies) who shall be entitled to receive the amounts payable with respect to an Award, if any, due under the Plan upon his death. A Participant may, from time to time, revoke or change his beneficiary designation without the consent of any prior beneficiary by filing a new designation with the Committee. The last such designation received by the Committee shall be controlling; provided, however, that no designation, or change or revocation thereof, shall be effective unless received by the Committee prior to the Participant’s death, and in no event shall it be effective as of a date prior to such receipt. If no beneficiary designation is filed by a Participant, the beneficiary shall be deemed to be his or her spouse or, if the Participant is unmarried at the time of death, his or her estate.

 

(g) Termination of Employment/Service. Unless determined otherwise by the Committee at any point following such event: (i) neither a temporary absence from employment or service due to illness, vacation or leave of absence nor a transfer from employment or service with the Company to employment or service with an Affiliate (or vice-versa) shall be considered a termination of employment or service with the Company or an Affiliate; and (ii) if a Participant’s employment with the Company and its Affiliates terminates, but such Participant continues to provide services to the Company and its Affiliates in a non-employee capacity (or vice-versa), such change in status shall not be considered a termination of employment with the Company or an Affiliate.

 

(h) Leaves of Absence/Transfer Between Locations. The Committee shall have the discretion to determine at any time whether and to what extent the vesting of Awards shall be suspended during any leave of absence; provided, however, that in the absence of such determination, vesting of Awards shall continue during any paid leave and during any unpaid leave (unless otherwise required by applicable laws). A Participant will not cease to be an Employee in the case of (a) any leave of absence approved by the Participant’s employer or (b) transfers between locations of the Company or between the Company or any Subsidiary. If an Employee is holding an Incentive Stock Option and such leave exceeds three (3) months then, for purposes of Incentive Stock Option status only, such Employee’s service as an Employee shall be deemed terminated on the first (1st) day following such three (3) month period and the Incentive Stock Option shall thereafter automatically treated for tax purposes as a Nonstatutory Stock Option in accordance with applicable laws, unless reemployment upon the expiration of such leave is guaranteed by contract or statute, or unless provided otherwise pursuant to a written Company policy.

 

(i) No Rights as a Stockholder. Except as otherwise specifically provided in the Plan or any Award Agreement, no person shall be entitled to the privileges of ownership in respect of Common Shares or other securities that are subject to Awards hereunder until such shares have been issued or delivered to that person.

 

A-22

 

 

(j) Government and Other Regulations.

 

(i) The obligation of the Company to settle Awards in Common Shares or other consideration shall be subject to all applicable laws, rules, and regulations, and to such approvals by governmental agencies as may be required. Notwithstanding any terms or conditions of any Award to the contrary, the Company shall be under no obligation to offer to sell or to sell, and shall be prohibited from offering to sell or selling, any Common Shares or other securities pursuant to an Award unless such shares have been properly registered for sale pursuant to the Securities Act with the Securities and Exchange Commission or unless the Company has received an opinion of counsel, satisfactory to the Company, that such shares may be offered or sold without such registration pursuant to an available exemption therefrom and the terms and conditions of such exemption have been fully complied with. The Company shall be under no obligation to register for sale under the Securities Act any of the Common Shares or other securities to be offered or sold under the Plan. The Committee shall have the authority to provide that all certificates for Common Shares or other securities of the Company or any Affiliate delivered under the Plan shall be subject to such stop transfer orders and other restrictions as the Committee may deem advisable under the Plan, the applicable Award Agreement, the federal securities laws, or the rules, regulations and other requirements of the Securities and Exchange Commission, any securities exchange or inter-dealer quotation system upon which such shares or other securities are then listed or quoted and any other applicable federal, state, local or non-U.S. laws, and, without limiting the generality of Section 9 of the Plan, the Committee may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions. Notwithstanding any provision in the Plan to the contrary, the Committee reserves the right to add any additional terms or provisions to any Award granted under the Plan that it in its sole discretion deems necessary or advisable in order that such Award complies with the legal requirements of any governmental entity to whose jurisdiction the Award is subject.

 

(ii) The Committee may cancel an Award or any portion thereof if it determines, in its sole discretion, that legal or contractual restrictions and/or blockage and/or other market considerations would make the Company’s acquisition of Common Shares from the public markets, the Company’s issuance of Common Shares or other securities to the Participant, the Participant’s acquisition of Common Shares or other securities from the Company and/or the Participant’s sale of Common Shares to the public markets, illegal, impracticable or inadvisable. If the Committee determines to cancel all or any portion of an Award denominated in Common Shares in accordance with the foregoing, the Company shall pay to the Participant an amount equal to the excess of (A) the aggregate fair market value of the Common Shares subject to such Award or portion thereof canceled (determined as of the applicable exercise date, or the date that the shares would have been vested or delivered, as applicable), over (B) the aggregate Exercise Price or Strike Price (in the case of an Option or SAR, respectively) or any amount payable as a condition of delivery of Common Shares (in the case of any other Award). Such amount shall be delivered to the Participant as soon as practicable following the cancellation of such Award or portion thereof.

 

(k) Payments to Persons Other Than Participants. If the Committee shall find that any person to whom any amount is payable under the Plan is unable to care for his affairs because of illness or accident, or is a minor, or has died, then any payment due to such person or his estate (unless a prior claim therefor has been made by a duly appointed legal representative) may, if the Committee so directs the Company, be paid to his spouse, child, relative, an institution maintaining or having custody of such person, or any other person deemed by the Committee to be a proper recipient on behalf of such person otherwise entitled to payment. Any such payment shall be a complete discharge of the liability of the Committee and the Company therefor.

 

A-23

 

 

(l) Nonexclusivity of the Plan. Neither the adoption of this Plan by the Board nor the submission of this Plan to the stockholders of the Company for approval shall be construed as creating any limitations on the power of the Board to adopt such other incentive arrangements as it may deem desirable, including, without limitation, the granting of stock options or other equity-based awards otherwise than under this Plan, and such arrangements may be either applicable generally or only in specific cases.

 

(m) No Trust or Fund Created. Neither the Plan nor any Award shall create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company or any Affiliate, on the one hand, and a Participant or other person or entity, on the other hand. No provision of the Plan or any Award shall require the Company, for the purpose of satisfying any obligations under the Plan, to purchase assets or place any assets in a trust or other entity to which contributions are made or otherwise to segregate any assets, nor shall the Company maintain separate bank accounts, books, records or other evidence of the existence of a segregated or separately maintained or administered fund for such purposes. Participants shall have no rights under the Plan other than as unsecured general creditors of the Company, except that insofar as they may have become entitled to payment of additional compensation by performance of services, they shall have the same rights as other employees under general law.

 

(n) Reliance on Reports. Each member of the Committee and each member of the Board shall be fully justified in acting or failing to act, as the case may be, and shall not be liable for having so acted or failed to act in good faith, in reliance upon any report made by the independent public accountant of the Company and its Affiliates and/or any other information furnished in connection with the Plan by any agent of the Company or the Committee or the Board, other than himself.

 

(o) Relationship to Other Benefits. No payment under the Plan shall be taken into account in determining any benefits under any pension, retirement, profit sharing, group insurance or other benefit plan of the Company except as otherwise specifically provided in such other plan.

 

(p) Governing Law. The Plan shall be governed by and construed in accordance with the internal laws of the State of Delaware applicable to contracts made and performed wholly within the State of Delaware, without giving effect to the conflict of laws provisions thereof. Each party hereby irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of the state and federal courts seated in Wilmington, Delaware (and any appellate courts thereof) in any action or proceeding arising out of or relating to this Plan, and each of the parties hereby irrevocably and unconditionally (a) agrees not to commence any such action or proceeding except in such courts, (b) agrees that any claim in respect of any such action or proceeding may be heard and determined in such court, (c) waives, to the fullest extent it may legally and effectively do so, any objection which it may now or hereafter have to the laying of venue of any such action or proceeding in any such court, and (d) waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court. Each party agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Each party hereby knowingly, voluntarily and intentionally irrevocably waives the right to a trial by jury in respect to any litigation, dispute, claim, legal action or other legal proceeding based hereon, or arising out of, under, or in connection with, this Plan.

 

A-24

 

 

(q) Severability. If any provision of the Plan or any Award or Award Agreement is or becomes or is deemed to be invalid, illegal, or unenforceable in any jurisdiction or as to any person or entity or Award, or would disqualify the Plan or any Award under any law deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to the applicable laws, or if it cannot be construed or deemed amended without, in the determination of the Committee, materially altering the intent of the Plan or the Award, such provision shall be construed or deemed stricken as to such jurisdiction, person or entity or Award and the remainder of the Plan and any such Award shall remain in full force and effect.

 

(r) Obligations Binding on Successors. The obligations of the Company under the Plan shall be binding upon any successor corporation or organization resulting from the merger, amalgamation, consolidation or other reorganization of the Company, or upon any successor corporation or organization succeeding to substantially all of the assets and business of the Company.

 

(s) Status under ERISA. It is the intent of the Company that the Plan shall not constitute an “employee benefit plan” for purposes of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended.

 

(t) Code Section 409A.

 

(i) Notwithstanding any provision of this Plan to the contrary, all Awards made under this Plan are intended to be exempt from or, in the alternative, comply with Code Section 409A and the interpretive guidance thereunder, including the exceptions for stock rights and short-term deferrals. The Plan shall be construed and interpreted in accordance with such intent. Each payment under an Award shall be treated as a separate payment for purposes of Code Section 409A.

 

(ii) If a Participant is a “specified employee” (as such term is defined for purposes of Code Section 409A) at the time of his or her termination of service, no amount that is nonqualified deferred compensation subject to Code Section 409A and that becomes payable by reason of such termination of service shall be paid to the Participant (or in the event of the Participant’s death, the Participant’s representative or estate) before the earlier of (x) the first business day after the date that is six months following the date of the Participant’s termination of service, and (y) within 30 days following the date of the Participant’s death. For purposes of Code Section 409A, a termination of service shall be deemed to occur only if it is a “separation from service” within the meaning of Code Section 409A, and references in the Plan and any Award Agreement to “termination of service” or similar terms shall mean a “separation from service.” If any Award is or becomes subject to Code Section 409A, unless the applicable Award Agreement provides otherwise, such Award shall be payable upon the Participant’s “separation from service” within the meaning of Code Section 409A. If any Award is or becomes subject to Code Section 409A and if payment of such Award would be accelerated or otherwise triggered under a Change in Control, then the definition of Change in Control shall be deemed modified, only to the extent necessary to avoid the imposition of an excise tax under Code Section 409A, to mean a “change in control event” as such term is defined for purposes of Code Section 409A.

 

A-25

 

 

(iii) Any adjustments made pursuant to Section 13 to Awards that are subject to Code Section 409A shall be made in compliance with the requirements of Code Section 409A, and any adjustments made pursuant to Section 13 to Awards that are not subject to Code Section 409A shall be made in such a manner as to ensure that after such adjustment, the Awards either (x) continue not to be subject to Code Section 409A or (y) comply with the requirements of Code Section 409A.

 

(u) Expenses; Gender; Titles and Headings. The expenses of administering the Plan shall be borne by the Company and its Affiliates. Masculine pronouns and other words of masculine gender shall refer to both men and women. The titles and headings of the sections in the Plan are for convenience of reference only, and in the event of any conflict, the text of the Plan, rather than such titles or headings shall control.

 

(v) Other Agreements. Notwithstanding the above, the Committee may require, as a condition to the grant of and/or the receipt of Common Shares or other securities under an Award, that the Participant execute lock-up, stockholder or other agreements, as it may determine in its sole and absolute discretion.

 

(w) Payments. Participants shall be required to pay, to the extent required by applicable law, any amounts required to receive Common Shares or other securities under any Award made under the Plan.

 

(x) Erroneously Awarded Compensation. All Awards shall be subject (including on a retroactive basis) to (i) any clawback, forfeiture or similar incentive compensation recoupment policy established from time to time by the Company, including, without limitation, any such policy established to comply with the Dodd-Frank Wall Street Reform and Consumer Protection Act, (ii) applicable law (including, without limitation, Section 304 of the Sarbanes-Oxley Act and Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act), and/or (iii) the rules and regulations of the applicable securities exchange or inter-dealer quotation system on which the Common Shares or other securities are listed or quoted, and such requirements shall be deemed incorporated by reference into all outstanding Award Agreements.

 

(y) Investment Representations. As a condition to the exercise of an Award, the Company may require the person exercising such Award to represent and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is required.

 

(z) Corporate Records Control. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the papering of the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents.

 

A-26

 

 

Exhibit 31.1

 

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Aaron Green, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of OneMedNet Corporation;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 16, 2026 By: /s/ Aaron Green
    Aaron Green
   

Chief Executive Officer

(Principal Executive Officer)

 

 

 

 

Exhibit 31.2

 

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Robert Golden, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of OneMedNet Corporation;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 16, 2026 By: /s/ Robert Golden
    Robert Golden
   

Chief Financial Officer

(Principal Financial Officer

and Principal Accounting Officer)

 

 

 

 

Exhibit 32.1

 

CERTIFICATIONS PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of OneMedNet Corporation (the “Company”) for the quarter ended September 30, 2026, as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), I, Aaron Green, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 16, 2026 By: /s/ Aaron Green
    Aaron Green
   

Chief Executive Officer

(Principal Executive Officer)

 

 

 

 

Exhibit 32.2

 

CERTIFICATIONS PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of OneMedNet Corporation (the “Company”) for the quarter ended September 30, 2026, as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), I, Robert Golden, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 16, 2026 By: /s/ Robert Golden
    Robert Golden
   

Chief Financial Officer

(Principal Financial Officer

and Principal Accounting Officer)

 

 

Keep reading